Evolving strategies for addressing CAR T-cell toxicities

1.

Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., Milone, M. C., Levine, B. L., & June, C. H. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. New England Journal of Medicine, 368(16), 1509–1518. https://doi.org/10.1056/NEJMoa1215134CrossRefPubMed

2.

Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., Go, W. Y., Eldjerou, L., Gardner, R. A., Frey, N., Curran, K. J., Peggs, K., Pasquini, M., DiPersio, J. F., van den Brink, M. R. M., . . . Neelapu, S. S. (2019). ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biology of Blood and Marrow Transplantation, 25(4), 625–638. https://doi.org/10.1016/j.bbmt.2018.12.758

3.

Bachy, E., Le Gouill, S., Di Blasi, R., Sesques, P., Manson, G., Cartron, G., Beauvais, D., Roulin, L., Gros, F. X., Rubio, M. T., Bories, P., Bay, J. O., Llorente, C. C., Choquet, S., Casasnovas, R. O., Mohty, M., Guidez, S., Joris, M., Loschi, M., . . . Morschhauser, F. (2022). A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nature Medicine, 28(10), 2145–2154. https://doi.org/10.1038/s41591-022-01969-y

4.

Frigault, M. J., Amoloja, T., Burke, L. M., Morariu-Zamfir, R., Bhatt, V., Bibeau, K., Tang, X. Y., Moskop, A., Maziarz, R. T., & DiPersio, J. F. (2023). Rates of cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) from Center for International Blood and Marrow Transplant Research (CIBMTR) data on US subjects (SUBJ) with lymphoma following chimeric antigen receptor T cell therapy (CAR-T). Journal of Clinical Oncology, 41(16_suppl), 7528–7528. https://doi.org/10.1200/JCO.2023.41.16_suppl.7528CrossRef

5.

Brammer, J. E., Braunstein, Z., Katapadi, A., Porter, K., Biersmith, M., Guha, A., Vasu, S., Yildiz, V. O., Smith, S. A., Buck, B., Haddad, D., Gumina, R., William, B. M., Penza, S., Saad, A., Denlinger, N., Vallakati, A., Baliga, R., Benza, R., . . . Addison, D. (2021). Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. Journal for Immunotherapy of Cancer, 9(8). https://doi.org/10.1136/jitc-2020-002303

6.

Tang, K., & Nastoupil, L. J. (2021). Real-world experiences of CAR T-cell therapy for large B-cell lymphoma: How similar are they to the prospective studies? J Immunother Precis Oncol, 4(3), 150–159. https://doi.org/10.36401/jipo-21-2

7.

Westin, J. R., Kersten, M. J., Salles, G., Abramson, J. S., Schuster, S. J., Locke, F. L., & Andreadis, C. (2021). Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA-1, and TRANSCEND trials. American Journal of Hematology, 96(10), 1295–1312. https://doi.org/10.1002/ajh.26301CrossRefPubMedPubMedCentral

8.

Pasquini, M. C., Hu, Z. H., Curran, K., Laetsch, T., Locke, F., Rouce, R., Pulsipher, M. A., Phillips, C. L., Keating, A., Frigault, M. J., Salzberg, D., Jaglowski, S., Sasine, J. P., Rosenthal, J., Ghosh, M., Landsburg, D., Margossian, S., Martin, P. L., Kamdar, M. K., . . . Grupp, S. (2020). Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. Blood Advances, 4(21), 5414–5424. https://doi.org/10.1182/bloodadvances.2020003092

9.

Maus, M. V., Alexander, S., Bishop, M. R., Brudno, J. N., Callahan, C., Davila, M. L., Diamonte, C., Dietrich, J., Fitzgerald, J. C., Frigault, M. J., Fry, T. J., Holter-Chakrabarty, J. L., Komanduri, K. V., Lee, D. W., Locke, F. L., Maude, S. L., McCarthy, P. L., Mead, E., Neelapu, S. S., . . . Grupp, S. A. (2020). Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events. Journal for Immunotherapy of Cancer, 8(2). https://doi.org/10.1136/jitc-2020-001511

10.

Kadauke, S., Myers, R. M., Li, Y., Aplenc, R., Baniewicz, D., Barrett, D. M., Barz Leahy, A., Callahan, C., Dolan, J. G., Fitzgerald, J. C., Gladney, W., Lacey, S. F., Liu, H., Maude, S. L., McGuire, R., Motley, L. S., Teachey, D. T., Wertheim, G. B., Wray, L., . . . Grupp, S. A. (2021). Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: A prospective clinical trial. Journal of Clinical Oncology, 39(8), 920–930. https://doi.org/10.1200/jco.20.02477

11.

Kittai, A. S., Huang, Y., Gordon, M., Denlinger, N., Mian, A., Fitzgerald, L., Bishop, J., Nagle, S., Stephens, D. M., Jaglowski, S., Hill, B., & Danilov, A. V. (2021). Comorbidities predict inferior survival in patients receiving chimeric antigen receptor T cell therapy for diffuse large B cell lymphoma: A multicenter analysis. Transplantation and Cellular Therapy, 27(1), 46–52. https://doi.org/10.1016/j.bbmt.2020.09.028CrossRefPubMed

12.

Santomasso, B. D., Gust, J., & Perna, F. (2023). How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity. Blood, 141(20), 2443–2451. https://doi.org/10.1182/blood.2022017604CrossRefPubMedPubMedCentral

13.

Aghajan, Y., Yu, A., Jacobson, C. A., Kim, A. I., Kean, L., Robertson, M., & Vaitkevicius, H. (2021). Myelopathy because of CAR-T-related neurotoxicity treated with siltuximab. Neurology: Clinical Practice, 11(6), e944–e946. https://doi.org/10.1212/cpj.0000000000001078CrossRefPubMed

14.

Shalabi, H., Harrison, C., Yates, B., Calvo, K. R., Lee, D. W., & Shah, N. N. (2024). Intrathecal hydrocortisone for treatment of children and young adults with CAR T-cell immune-effector cell-associated neurotoxicity syndrome. Pediatric Blood & Cancer, 71(1), e30741. https://doi.org/10.1002/pbc.30741CrossRef

15.

Cohen, A. D., Parekh, S., Santomasso, B. D., Gállego Pérez-Larraya, J., van de Donk, N., Arnulf, B., Mateos, M. V., Lendvai, N., Jackson, C. C., De Braganca, K. C., Schecter, J. M., Marquez, L., Lee, E., Cornax, I., Zudaire, E., Li, C., Olyslager, Y., Madduri, D., Varsos, H., . . . Jagannath, S. (2022). Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer Journal, 12(2), 32. https://doi.org/10.1038/s41408-022-00629-1

16.

Hill, J. A., & Seo, S. K. (2020). How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood, 136(8), 925–935. https://doi.org/10.1182/blood.2019004000CrossRefPubMedPubMedCentral

17.

Hines, M. R., Knight, T. E., McNerney, K. O., Leick, M. B., Jain, T., Ahmed, S., Frigault, M. J., Hill, J. A., Jain, M. D., Johnson, W. T., Lin, Y., Mahadeo, K. M., Maron, G. M., Marsh, R. A., Neelapu, S. S., Nikiforow, S., Ombrello, A. K., Shah, N. N., Talleur, A. C., . . . Shah, N. N. (2023). Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplantation and Cellular Therapy, 29(7), 438.e431–438.e416. https://doi.org/10.1016/j.jtct.2023.03.006

18.

Locatelli, F., Jordan, M. B., Allen, C., Cesaro, S., Rizzari, C., Rao, A., Degar, B., Garrington, T. P., Sevilla, J., Putti, M. C., Fagioli, F., Ahlmann, M., Dapena Diaz, J. L., Henry, M., De Benedetti, F., Grom, A., Lapeyre, G., Jacqmin, P., Ballabio, M., & de Min, C. (2020). Emapalumab in children with primary hemophagocytic lymphohistiocytosis. New England Journal of Medicine, 382(19), 1811–1822. https://doi.org/10.1056/NEJMoa1911326CrossRefPubMed

19.

Porter, T. J., Lazarevic, A., Ziggas, J. E., Fuchs, E., Kim, K., Byrnes, H., Luznik, L., Bolaños-Meade, J., Ali, S. A., Shah, N. N., Wagner-Johnston, N., & Jain, T. (2022). Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel. British Journal of Haematology, 199(5), 720–727. https://doi.org/10.1111/bjh.18454CrossRefPubMedPubMedCentral

20.

Rejeski, K., Subklewe, M., Aljurf, M., Bachy, E., Balduzzi, A., Barba, P., Bruno, B., Benjamin, R., Carrabba, M. G., Chabannon, C., Ciceri, F., Corradini, P., Delgado, J., Di Blasi, R., Greco, R., Houot, R., Iacoboni, G., Jäger, U., Kersten, M. J., . . . Yakoub-Agha, I. (2023). Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood, 142(10), 865–877. https://doi.org/10.1182/blood.2023020578

21.

McNerney, K. O., Si Lim, S. J., Ishikawa, K., Dreyzin, A., Vatsayan, A., Chen, J. J., Baggott, C., Prabhu, S., Pacenta, H. L., Philips, C., Rossoff, J., Stefanski, H. E., Talano, J. A., Moskop, A., Verneris, M., Myers, D., Karras, N. A., Brown, P., Bonifant, C. L., . . . Schultz, L. M. (2023). HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL. Blood Advances, 7(12), 2758–2771. https://doi.org/10.1182/bloodadvances.2022008893

22.

Johnsrud, A., Craig, J., Baird, J., Spiegel, J., Muffly, L., Zehnder, J., Tamaresis, J., Negrin, R., Johnston, L., Arai, S., Shizuru, J., Lowsky, R., Meyer, E., Weng, W. K., Shiraz, P., Rezvani, A., Latchford, T., Mackall, C., Miklos, D., . . . Sidana, S. (2021). Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy. Blood Advances, 5(21), 4465–4475. https://doi.org/10.1182/bloodadvances.2021004716

23.

Mahdi, J., Dietrich, J., Straathof, K., Roddie, C., Scott, B. J., Davidson, T. B., Prolo, L. M., Batchelor, T. T., Campen, C. J., Davis, K. L., Gust, J., Lim, M., Majzner, R. G., Park, J. R., Partap, S., Ramakrishna, S., Richards, R., Schultz, L., Vitanza, N. A., . . . Monje, M. (2023). Tumor inflammation-associated neurotoxicity. Nature Medicine, 29(4), 803–810. https://doi.org/10.1038/s41591-023-02276-w

24.

Majzner, R. G., Ramakrishna, S., Yeom, K. W., Patel, S., Chinnasamy, H., Schultz, L. M., Richards, R. M., Jiang, L., Barsan, V., Mancusi, R., Geraghty, A. C., Good, Z., Mochizuki, A. Y., Gillespie, S. M., Toland, A. M. S., Mahdi, J., Reschke, A., Nie, E. H., Chau, I. J., . . . Monje, M. (2022). GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature, 603(7903), 934–941. https://doi.org/10.1038/s41586-022-04489-4

25.

Appa, A. A., Jain, R., Rakita, R. M., Hakimian, S., & Pottinger, P. S. (2017). Characterizing cefepime neurotoxicity: A systematic review. Open Forum Infectious Diseases, 4(4), ofx70. https://doi.org/10.1093/ofid/ofx170CrossRef

26.

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis, K. L., Martin, P. L., Nemecek, E. R., Yanik, G. A., Peters, C., . . . Grupp, S. A. (2018). Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New England Journal of Medicine, 378(5), 439–448. https://doi.org/10.1056/NEJMoa1709866

27.

Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L., Chavez, J. C., Bachy, E., Kato, K., Harigae, H., Kersten, M. J., Andreadis, C., Riedell, P. A., Ho, P. J., Pérez-Simón, J. A., Chen, A. I., Nastoupil, L. J., . . . Thieblemont, C. (2022). Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: The phase 2 ELARA trial. Nature Medicine, 28(2), 325–332. https://doi.org/10.1038/s41591-021-01622-0

28.

Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., Morschhauser, F., Janz, M., Flinn, I., Rabitsch, W., Kwong, Y. L., Kersten, M. J., Minnema, M. C., Holte, H., Chan, E. H. L., . . . Westin, J. R. (2022). Second-line tisagenlecleucel or standard care in aggressive B-cell lymphoma. N Engl J Med, 386(7), 629–639. https://doi.org/10.1056/NEJMoa2116596

29.

Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., Fleury, I., Bachanova, V., Foley, S. R., Ho, P. J., Mielke, S., Magenau, J. M., Holte, H., Pantano, S., Pacaud, L. B., . . . Maziarz, R. T. (2019). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. New England Journal of Medicine, 380(1), 45–56. https://doi.org/10.1056/NEJMoa1804980

30.

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., Stiff, P. J., Friedberg, J. W., Flinn, I. W., Goy, A., Hill, B. T., Smith, M. R., Deol, A., Farooq, U., . . . Go, W. Y. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 377(26), 2531–2544. https://doi.org/10.1056/NEJMoa1707447

31.

Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., Reshef, R., Leslie, L. A., Yakoub-Agha, I., Oluwole, O. O., Fung, H. C. H., Rosenblatt, J., Rossi, J. M., Goyal, L., Plaks, V., . . . Neelapu, S. S. (2022). Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): A single-arm, multicentre, phase 2 trial. The Lancet Haematology, 23(1), 91–103. https://doi.org/10.1016/s1470-2045(21)00591-x

32.

Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M. A., Kersten, M. J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., Muñoz, J., Farooq, U., van Meerten, T., Reagan, P. M., Sureda, A., Flinn, I. W., Vandenberghe, P., Song, K. W., Dickinson, M., . . . Westin, J. R. (2022). Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. New England Journal of Medicine, 386(7), 640–654. https://doi.org/10.1056/NEJMoa2116133

33.

Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., McSweeney, P. A., Miklos, D. B., Pagel, J. M., Kersten, M. J., Milpied, N., Fung, H., Topp, M. S., Houot, R., Beitinjaneh, A., . . . Reagan, P. M. (2020). KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. New England Journal of Medicine, 382(14), 1331–1342. https://doi.org/10.1056/NEJMoa1914347

34.

Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Leguay, T., Bishop, M. R., Topp, M. S., Tzachanis, D., O'Dwyer, K. M., Arellano, M. L., Lin, Y., Baer, M. R., Schiller, G. J., Park, J. H., Subklewe, M., Abedi, M., Minnema, M. C., . . . Houot, R. (2021). KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: Phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet, 398(10299), 491–502. https://doi.org/10.1016/s0140-6736(21)01222-8

35.

Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., Sehgal, A., Solomon, S. R., Ghosh, N., Albertson, T. M., Garcia, J., Kostic, A., Mallaney, M., Ogasawara, K., Newhall, K., . . . Siddiqi, T. (2020). Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study. Lancet, 396(10254), 839–852. https://doi.org/10.1016/s0140-6736(20)31366-0

36.

Kamdar, M., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., Izutsu, K., Morschhauser, F., Lunning, M., Maloney, D. G., Crotta, A., Montheard, S., Previtali, A., Stepan, L., Ogasawara, K., . . . Abramson, J. S. (2022). Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet, 399(10343), 2294–2308. https://doi.org/10.1016/s0140-6736(22)00662-6

37.

Sehgal, A., Hoda, D., Riedell, P. A., Ghosh, N., Hamadani, M., Hildebrandt, G. C., Godwin, J. E., Reagan, P. M., Wagner-Johnston, N., Essell, J., Nath, R., Solomon, S. R., Champion, R., Licitra, E., Fanning, S., Gupta, N., Dubowy, R., D'Andrea, A., Wang, L., . . . Gordon, L. I. (2022). Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): An open-label, phase 2 study. Lancet Oncology, 23(8), 1066–1077. https://doi.org/10.1016/s1470-2045(22)00339-4

38.

Munshi, N. C., Anderson, L. D., Jr., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., Moreau, P., Yakoub-Agha, I., Delforge, M., Cavo, M., Einsele, H., Goldschmidt, H., Weisel, K., Rambaldi, A., Reece, D., . . . San-Miguel, J. (2021). Idecabtagene vicleucel in relapsed and refractory multiple myeloma. New England Journal of Medicine, 384(8), 705–716. https://doi.org/10.1056/NEJMoa2024850

39.

Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., Bahlis, N. J., Moreau, P., Solomon, S. R., Delforge, M., Berdeja, J., Truppel-Hartmann, A., Yang, Z., Favre-Kontula, L., Wu, F., . . . Giralt, S. (2023). Ide-cel or standard regimens in relapsed and refractory multiple myeloma. New England Journal of Medicine, 388(11), 1002–1014. https://doi.org/10.1056/NEJMoa2213614

40.

Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., Deol, A., Munshi, N. C., O'Donnell, E., Avigan, D., Singh, I., Zudaire, E., Yeh, T. M., Allred, A. J., Olyslager, Y., . . . Jagannath, S. (2021). Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b/2 open-label study. Lancet, 398(10297), 314–324. https://doi.org/10.1016/s0140-6736(21)00933-8

41.

San-Miguel, J., Dhakal, B., Yong, K., Spencer, A., Anguille, S., Mateos, M. V., Fernández de Larrea, C., Martínez-López, J., Moreau, P., Touzeau, C., Leleu, X., Avivi, I., Cavo, M., Ishida, T., Kim, S. J., Roeloffzen, W., van de Donk, N., Dytfeld, D., Sidana, S., . . . Einsele, H. (2023). Cilta-cel or standard care in lenalidomide-refractory multiple myeloma. New England Journal of Medicine, 389(4), 335–347. https://doi.org/10.1056/NEJMoa2303379

42.

Le, R. Q., Li, L., Yuan, W., Shord, S. S., Nie, L., Habtemariam, B. A., Przepiorka, D., Farrell, A. T., & Pazdur, R. (2018). FDA approval summary: Tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. The Oncologist, 23(8), 943–947. https://doi.org/10.1634/theoncologist.2018-0028CrossRefPubMedPubMedCentral

43.

Caimi, P. F., Pacheco Sanchez, G., Sharma, A., Otegbeye, F., Ahmed, N., Rojas, P., Patel, S., Kleinsorge Block, S., Schiavone, J., Zamborsky, K., Boughan, K., Hillian, A., Reese-Koc, J., Maschan, M., Dropulic, B., Sekaly, R. P., & de Lima, M. (2021). Prophylactic tocilizumab prior to anti-CD19 CAR-T cell therapy for non-Hodgkin lymphoma. Frontiers in Immunology, 12, 745320. https://doi.org/10.3389/fimmu.2021.745320CrossRefPubMedPubMedCentral

44.

Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., Qu, J., Wasielewska, T., He, Q., Fink, M., Shinglot, H., Youssif, M., Satter, M., Wang, Y., Hosey, J., . . . Brentjens, R. (2014). Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Transplantation and Cellular Therapy, 6(224), 224ra225. https://doi.org/10.1126/scitranslmed.3008226

45.

Teachey, D. T., Bishop, M. R., Maloney, D. G., & Grupp, S. A. (2018). Toxicity management after chimeric antigen receptor T cell therapy: One size does not fit ‘ALL.’ Nature Reviews. Clinical Oncology, 15(4), 218. https://doi.org/10.1038/nrclinonc.2018.19CrossRefPubMed

46.

Liu, S., Deng, B., Yin, Z., Pan, J., Lin, Y., Ling, Z., Wu, T., Chen, D., Chang, A. H., Gao, Z., Song, Y., Zhao, Y., & Tong, C. (2020). Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer Journal, 10(2), 15. https://doi.org/10.1038/s41408-020-0280-yCrossRefPubMedPubMedCentral

47.

Gardner, R. A., Ceppi, F., Rivers, J., Annesley, C., Summers, C., Taraseviciute, A., Gust, J., Leger, K. J., Tarlock, K., Cooper, T. M., Finney, O. C., Brakke, H., Li, D. H., Park, J. R., & Jensen, M. C. (2019). Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy. Blood, 134(24), 2149–2158. https://doi.org/10.1182/blood.2019001463CrossRefPubMedPubMedCentral

48.

Shah, B. D., Bishop, M. R., Oluwole, O. O., Logan, A. C., Baer, M. R., Donnellan, W. B., O'Dwyer, K. M., Holmes, H., Arellano, M. L., Ghobadi, A., Pagel, J. M., Lin, Y., Cassaday, R. D., Park, J. H., Abedi, M., Castro, J. E., DeAngelo, D. J., Malone, A. K., Mawad, R., . . . Wierda, W. G. (2021). KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood, 138(1), 11–22. https://doi.org/10.1182/blood.2020009098

49.

Jain, M. D., Smith, M., & Shah, N. N. (2023). How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood, 141(20), 2430–2442. https://doi.org/10.1182/blood.2022017414CrossRefPubMedPubMedCentral

50.

Frey, N. V., Shaw, P. A., Hexner, E. O., Pequignot, E., Gill, S., Luger, S. M., Mangan, J. K., Loren, A. W., Perl, A. E., Maude, S. L., Grupp, S. A., Shah, N. N., Gilmore, J., Lacey, S. F., Melenhorst, J. J., Levine, B. L., June, C. H., & Porter, D. L. (2020). Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia. Journal of Clinical Oncology, 38(5), 415–422. https://doi.org/10.1200/jco.19.01892CrossRefPubMed

51.

Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., Westin, J., Gulbis, A. M., Loghin, M. E., de Groot, J. F., Adkins, S., Davis, S. E., Rezvani, K., Hwu, P., & Shpall, E. J. (2018). Chimeric antigen receptor T-cell therapy - Assessment and management of toxicities. Nature Reviews. Clinical Oncology, 15(1), 47–62. https://doi.org/10.1038/nrclinonc.2017.148CrossRefPubMed

52.

Papadouli, I., Mueller-Berghaus, J., Beuneu, C., Ali, S., Hofner, B., Petavy, F., Tzogani, K., Miermont, A., Norga, K., Kholmanskikh, O., Leest, T., Schuessler-Lenz, M., Salmonson, T., Gisselbrecht, C., Garcia, J. L., & Pignatti, F. (2020). EMA review of axicabtagene ciloleucel (Yescarta) for the treatment of diffuse large B-Cell lymphoma. The Oncologist, 25(10), 894–902. https://doi.org/10.1634/theoncologist.2019-0646CrossRefPubMedPubMedCentral

53.

Jacobson, C. A., Munoz, J., Sun, F., Kanters, S., Limbrick-Oldfield, E. H., Spooner, C., Mignone, K., Ayuk, F., Sanderson, R., Whitmore, J., Wang, Y., Xu, H., & Dickinson, M. (2024). Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: A systematic review and meta-analysis. Transplantation and Cellular Therapy, 30(1), 77.e71-77.e15. https://doi.org/10.1016/j.jtct.2023.10.017CrossRef

54.

Santomasso, B. D., Nastoupil, L. J., Adkins, S., Lacchetti, C., Schneider, B. J., Anadkat, M., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., Davies, M. J., Ernstoff, M. S., Fecher, L., Funchain, P., Jaiyesimi, I., Mammen, J. S., Naidoo, J., Naing, A., Phillips, T., . . . Ghosh, M. (2021). Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. Journal of Clinical Oncology, 39(35), 3978–3992. https://doi.org/10.1200/jco.21.01992

55.

Nair, R., Drillet, G., Lhomme, F., Le Bras, A., Michel, L., Rossi, J., Sherman, M., Xue, A., Kerber, A., Jittapiromsak, N., Chi, L., Tummala, S., Neelapu, S. S., & Houot, R. (2021). Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy. Haematologica, 106(5), 1504–1506. https://doi.org/10.3324/haematol.2020.259952CrossRefPubMed

56.

Parker, K. R., Migliorini, D., Perkey, E., Yost, K. E., Bhaduri, A., Bagga, P., Haris, M., Wilson, N. E., Liu, F., Gabunia, K., Scholler, J., Montine, T. J., Bhoj, V. G., Reddy, R., Mohan, S., Maillard, I., Kriegstein, A. R., June, C. H., Chang, H. Y., . . . Satpathy, A. T. (2020). Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell, 183(1), 126–142.e117. https://doi.org/10.1016/j.cell.2020.08.022

57.

Sheikh, S., Mokhtari, S., Silverman, J. A., Reid, K., Faramand, R., Davila, M. L., Franke, N., Locke, F. L., Jain, M. D., Wong, D., & Kuruvilla, J. G. (2022). Transverse myelitis after anti-CD19 directed CAR T cell therapy for relapsed large B cell lymphoma. EJHaem, 3(1), 223–227. https://doi.org/10.1002/jha2.286CrossRefPubMed

58.

Kathari, Y. K., Ahmad, H., Kallen, M. E., Koka, R., Omili, D., Iraguha, T., Clement, J., Pham, L., Khalid, M., Fan, X., Gebru, E., Lesho, P., Park, E., Dishanthan, N., Baker, J. M., Dietze, K. A., Hankey, K. G., Badros, A., Yared, J. A., . . . Atanackovic, D. (2024). Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells. Haematologica, 109(2), 682–688. https://doi.org/10.3324/haematol.2023.283296

59.

Kuboki, M., Umezawa, Y., Motomura, Y., Okada, K., Nogami, A., Nagao, T., Miura, O., & Yamamoto, M. (2021). Severe motor weakness due to disturbance in peripheral nerves following tisagenlecleucel treatment. In Vivo, 35(6), 3407–3411. https://doi.org/10.21873/invivo.12640CrossRefPubMedPubMedCentral

60.

Badar, T., Johnson, B. D., & Hamadani, M. (2021). Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma. Bone Marrow Transplantation, 56(3), 683–685. https://doi.org/10.1038/s41409-020-01029-4CrossRefPubMed

61.

Hoogland, A. I., Barata, A., Logue, J., Kommalapati, A., Hyland, K. A., Nelson, A. M., Eisel, S. L., Small, B. J., James, B. W., Christy, S. M., Bulls, H. W., Booth-Jones, M., Jayani, R. V., Jain, M. D., Mokhtari, S., Chavez, J. C., Lazaryan, A., Shah, B. D., Locke, F. L., & Jim, H. S. L. (2022). Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy. Transplantation and Cellular Therapy, 28(6), 305.e301-305.e309. https://doi.org/10.1016/j.jtct.2022.03.023CrossRef

62.

Mailankody, S., Devlin, S. M., Landa, J., Nath, K., Diamonte, C., Carstens, E. J., Russo, D., Auclair, R., Fitzgerald, L., Cadzin, B., Wang, X., Sikder, D., Senechal, B., Bermudez, V. P., Purdon, T. J., Hosszu, K., McAvoy, D. P., Farzana, T., Mead, E., . . . Smith, E. L. (2022). GPRC5D-targeted CAR T cells for myeloma. New England Journal of Medicine, 387(13), 1196–1206. https://doi.org/10.1056/NEJMoa2209900

63.

Tomblyn, M., Chiller, T., Einsele, H., Gress, R., Sepkowitz, K., Storek, J., Wingard, J. R., Young, J. A., & Boeckh, M. J. (2009). Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: A global perspective. Biology of Blood and Marrow Transplantation, 15(10), 1143–1238. https://doi.org/10.1016/j.bbmt.2009.06.019CrossRefPubMedPubMedCentral

64.

Pihlgren, M., Schallert, N., Tougne, C., Bozzotti, P., Kovarik, J., Fulurija, A., Kosco-Vilbois, M., Lambert, P. H., & Siegrist, C. A. (2001). Delayed and deficient establishment of the long-term bone marrow plasma cell pool during early life. European Journal of Immunology, 31(3), 939–946. https://doi.org/10.1002/1521-4141(200103)31:3%3c939::aid-immu939%3e3.0.co;2-iCrossRefPubMed

65.

Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., Deol, A., Reagan, P. M., Stiff, P., Flinn, I. W., Farooq, U., Goy, A., McSweeney, P. A., Munoz, J., Siddiqi, T., . . . Neelapu, S. S. (2019). Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1–2 trial. Lancet Oncology, 20(1), 31–42. https://doi.org/10.1016/s1470-2045(18)30864-7

66.

Haidar, G., Dorritie, K., Farah, R., Bogdanovich, T., Nguyen, M. H., & Samanta, P. (2020). Invasive mold infections after chimeric antigen receptor-modified T-cell therapy: A case series, review of the literature, and implications for prophylaxis. Clinical Infectious Diseases, 71(3), 672–676. https://doi.org/10.1093/cid/ciz1127CrossRefPubMed

67.

Trottestam, H., Horne, A., Aricò, M., Egeler, R. M., Filipovich, A. H., Gadner, H., Imashuku, S., Ladisch, S., Webb, D., Janka, G., & Henter, J. I. (2011). Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: Long-term results of the HLH-94 treatment protocol. Blood, 118(17), 4577–4584. https://doi.org/10.1182/blood-2011-06-356261CrossRefPubMedPubMedCentral

68.

Fugere, T., Baltz, A., Mukherjee, A., Gaddam, M., Varma, A., Veeraputhiran, M., & Gentille Sanchez, C. G. (2023). Immune effector cell-associated HLH-like syndrome: A review of the literature of an increasingly recognized entity. Cancers (Basel), 15(21), 5149. https://doi.org/10.3390/cancers15215149CrossRefPubMed

69.

Jain, T., Olson, T. S., & Locke, F. L. (2023). How I treat cytopenias after CAR T-cell therapy. Blood, 141(20), 2460–2469. https://doi.org/10.1182/blood.2022017415CrossRefPubMedPubMedCentral

70.

Miller, K. C., Johnson, P. C., Abramson, J. S., Soumerai, J. D., Yee, A. J., Branagan, A. R., O’Donnell, E. K., Saucier, A., Jacobson, C. A., Frigault, M. J., & Raje, N. S. (2022). Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer Journal, 12(10), 146. https://doi.org/10.1038/s41408-022-00741-2CrossRefPubMedPubMedCentral

71.

Sterner, R. M., Sakemura, R., Cox, M. J., Yang, N., Khadka, R. H., Forsman, C. L., Hansen, M. J., Jin, F., Ayasoufi, K., Hefazi, M., Schick, K. J., Walters, D. K., Ahmed, O., Chappell, D., Sahmoud, T., Durrant, C., Nevala, W. K., Patnaik, M. M., Pease, L. R., . . . Kenderian, S. S. (2019). GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood, 133(7), 697–709. https://doi.org/10.1182/blood-2018-10-881722

72.

Peffault de Latour, R., Kulasekararaj, A., Iacobelli, S., Terwel, S. R., Cook, R., Griffin, M., Halkes, C. J. M., Recher, C., Barraco, F., Forcade, E., Vallejo, J. C., Drexler, B., Mear, J. B., Smith, A. E., Angelucci, E., Raymakers, R. A. P., de Groot, M. R., Daguindau, E., Nur, E., . . . Risitano, A. M. (2022). Eltrombopag added to immunosuppression in severe aplastic anemia. New England Journal of Medicine, 386(1), 11–23. https://doi.org/10.1056/NEJMoa2109965

73.

Gagelmann, N., Wulf, G. G., Duell, J., Glass, B., van Heteren, P., von Tresckow, B., Fischer, M., Penack, O., Ayuk, F., Einsele, H., Holtick, U., Thomson, J., Dreger, P., & Kröger, N. (2023). Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: A GLA/DRST study. Blood Advances, 7(4), 555–559. https://doi.org/10.1182/bloodadvances.2022008042CrossRefPubMed

74.

Jain, T., Knezevic, A., Pennisi, M., Chen, Y., Ruiz, J. D., Purdon, T. J., Devlin, S. M., Smith, M., Shah, G. L., Halton, E., Diamonte, C., Scordo, M., Sauter, C. S., Mead, E., Santomasso, B. D., Palomba, M. L., Batlevi, C. W., Maloy, M. A., Giralt, S., . . . Mailankody, S. (2020). Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. Blood Advances, 4(15), 3776–3787. https://doi.org/10.1182/bloodadvances.2020002509

75.

Lichtenstein, D. A., Schischlik, F., Shao, L., Steinberg, S. M., Yates, B., Wang, H. W., Wang, Y., Inglefield, J., Dulau-Florea, A., Ceppi, F., Hermida, L. C., Stringaris, K., Dunham, K., Homan, P., Jailwala, P., Mirazee, J., Robinson, W., Chisholm, K. M., Yuan, C., . . . Shah, N. N. (2021). Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood, 138(24), 2469–2484. https://doi.org/10.1182/blood.2021011898

76.

Ma, L., Dou, Y., Liu, R., Xu, T., Yang, F., Xue, F., Zheng, P., Feng, S., Guo, Y., Shi, H., Deng, B., Ke, X., & Hu, K. (2022). P1206: Gastrointestinal bleeding significantly reduced the efficacy and survival of Cd19 Car-T cell therapy in patients with gastrointestinal tract involvement of refractory/relapsed B-cell lymphoma. Hemasphere., 6(Suppl), 1092-1093. 1010.1097/1001.HS1099.0000847688.0000801787.0000847613. eCollection 0000842022 Jun

77.

Jess, J., Yates, B., Dulau-Florea, A., Parker, K., Inglefield, J., Lichtenstein, D., Schischlik, F., Ongkeko, M., Wang, Y., Shahani, S., Cullinane, A., Smith, H., Kane, E., Little, L., Chen, D., Fry, T. J., Shalabi, H., Wang, H. W., Satpathy, A., . . . Shah, N. N. (2023). CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity. Journal for Immunotherapy of Cancer, 11(6). https://doi.org/10.1136/jitc-2022-005898

78.

Buechner, J., Grupp, S. A., Hiramatsu, H., Teachey, D. T., Rives, S., Laetsch, T. W., Yanik, G. A., Wood, P., Awasthi, R., Yi, L., Chassot-Agostinho, A., Eldjerou, L. K., & De Moerloose, B. (2021). Practical guidelines for monitoring and management of coagulopathy following tisagenlecleucel CAR T-cell therapy. Blood Advances, 5(2), 593–601. https://doi.org/10.1182/bloodadvances.2020002757CrossRefPubMedPubMedCentral

79.

Jiang, H., Liu, L., Guo, T., Wu, Y., Ai, L., Deng, J., Dong, J., Mei, H., & Hu, Y. (2019). Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy. Annals of Hematology, 98(7), 1721–1732. https://doi.org/10.1007/s00277-019-03685-zCrossRefPubMed

80.

Wang, Y., Qi, K., Cheng, H., Cao, J., Shi, M., Qiao, J., Yan, Z., Jing, G., Pan, B., Sang, W., Li, D., Wang, X., Fu, C., Zhu, F., Zheng, J., Li, Z., & Xu, K. (2020). Coagulation disorders after chimeric antigen receptor T cell therapy: Analysis of 100 patients with relapsed and refractory hematologic malignancies. Biology of Blood and Marrow Transplantation, 26(5), 865–875. https://doi.org/10.1016/j.bbmt.2019.11.027CrossRefPubMed

81.

Bagley, S. J., Logun, M., Fraietta, J. A., Wang, X., Desai, A. S., Bagley, L. J., Nabavizadeh, A., Jarocha, D., Martins, R., Maloney, E., Lledo, L., Stein, C., Marshall, A., Leskowitz, R., Jadlowsky, J. K., Christensen, S., Oner, B. S., Plesa, G., Brennan, A., . . . O'Rourke, D. M. (2024). Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: Phase 1 trial interim results. Nature Medicine, 30(5), 1320–1329. https://doi.org/10.1038/s41591-024-02893-z

82.

Gill, S., Tasian, S. K., Ruella, M., Shestova, O., Li, Y., Porter, D. L., Carroll, M., Danet-Desnoyers, G., Scholler, J., Grupp, S. A., June, C. H., & Kalos, M. (2014). Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood, 123(15), 2343–2354. https://doi.org/10.1182/blood-2013-09-529537CrossRefPubMedPubMedCentral

83.

Kenderian, S. S., Ruella, M., Shestova, O., Klichinsky, M., Aikawa, V., Morrissette, J. J., Scholler, J., Song, D., Porter, D. L., Carroll, M., June, C. H., & Gill, S. (2015). CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia. Leukemia, 29(8), 1637–1647. https://doi.org/10.1038/leu.2015.52CrossRefPubMedPubMedCentral

84.

Richman, S. A., Nunez-Cruz, S., Moghimi, B., Li, L. Z., Gershenson, Z. T., Mourelatos, Z., Barrett, D. M., Grupp, S. A., & Milone, M. C. (2018). High-affinity GD2-specific CAR T cells induce fatal encephalitis in a preclinical neuroblastoma model. Cancer Immunology Research, 6(1), 36–46. https://doi.org/10.1158/2326-6066.Cir-17-0211CrossRefPubMed

85.

Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010). Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Molecular Therapy, 18(4), 843–851. https://doi.org/10.1038/mt.2010.24CrossRefPubMedPubMedCentral

86.

Thistlethwaite, F. C., Gilham, D. E., Guest, R. D., Rothwell, D. G., Pillai, M., Burt, D. J., Byatte, A. J., Kirillova, N., Valle, J. W., Sharma, S. K., Chester, K. A., Westwood, N. B., Halford, S. E. R., Nabarro, S., Wan, S., Austin, E., & Hawkins, R. E. (2017). The clinical efficacy of first-generation carcinoembryonic antigen (CEACAM5)-specific CAR T cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity. Cancer Immunology, Immunotherapy, 66(11), 1425–1436. https://doi.org/10.1007/s00262-017-2034-7CrossRefPubMedPubMedCentral

87.

Hassan, R., Butler, M., O’Cearbhaill, R. E., Oh, D. Y., Johnson, M., Zikaras, K., Smalley, M., Ross, M., Tanyi, J. L., Ghafoor, A., Shah, N. N., Saboury, B., Cao, L., Quintás-Cardama, A., & Hong, D. (2023). Mesothelin-targeting T cell receptor fusion construct cell therapy in refractory solid tumors: Phase 1/2 trial interim results. Nature Medicine, 29(8), 2099–2109. https://doi.org/10.1038/s41591-023-02452-yCrossRefPubMedPubMedCentral

88.

Linette, G. P., Stadtmauer, E. A., Maus, M. V., Rapoport, A. P., Levine, B. L., Emery, L., Litzky, L., Bagg, A., Carreno, B. M., Cimino, P. J., Binder-Scholl, G. K., Smethurst, D. P., Gerry, A. B., Pumphrey, N. J., Bennett, A. D., Brewer, J. E., Dukes, J., Harper, J., Tayton-Martin, H. K., . . . June, C. H. (2013). Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood, 122(6), 863–871. https://doi.org/10.1182/blood-2013-03-490565

89.

Myers, R. M., Jacoby, E., Pulsipher, M. A., Pasquini, M. C., Grupp, S. A., Shah, N. N., Laetsch, T. W., Curran, K. J., & Schultz, L. M. (2023). INSPIRED Symposium part 1: Clinical variables associated with improved outcomes for children and young adults treated with chimeric antigen receptor T cells for B cell acute lymphoblastic leukemia. Transplant Cell Therapy, 29(10), 598–607. https://doi.org/10.1016/j.jtct.2023.07.016CrossRef

90.

Cappell, K. M., & Kochenderfer, J. N. (2023). Long-term outcomes following CAR T cell therapy: What we know so far. Nature Reviews. Clinical Oncology, 20(6), 359–371. https://doi.org/10.1038/s41571-023-00754-1CrossRefPubMedPubMedCentral

91.

Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., Barrett, D. M., Weiss, S. L., Fitzgerald, J. C., Berg, R. A., Aplenc, R., Callahan, C., Rheingold, S. R., Zheng, Z., Rose-John, S., . . . Grupp, S. A. (2016). Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discovery, 6(6), 664–679. https://doi.org/10.1158/2159-8290.Cd-16-0040

92.

Hay, K. A., Hanafi, L. A., Li, D., Gust, J., Liles, W. C., Wurfel, M. M., López, J. A., Chen, J., Chung, D., Harju-Baker, S., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., & Turtle, C. J. (2017). Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood, 130(21), 2295–2306. https://doi.org/10.1182/blood-2017-06-793141CrossRefPubMedPubMedCentral

93.

Gust, J., Taraseviciute, A., & Turtle, C. J. (2018). Neurotoxicity associated with CD19-targeted CAR-T cell therapies. CNS Drugs, 32(12), 1091–1101. https://doi.org/10.1007/s40263-018-0582-9CrossRefPubMedPubMedCentral

94.

Schultz, L. M., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J. A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., Satwani, P., Krupski, C., Keating, A. K., . . . Laetsch, T. W. (2022). Disease burden affects outcomes in pediatric and young adult B-cell lymphoblastic leukemia after commercial tisagenlecleucel: A Pediatric Real-World Chimeric Antigen Receptor Consortium report. Journal of Clinical Oncology, 40(9), 945–955. https://doi.org/10.1200/jco.20.03585

95.

Myers, R. M., Taraseviciute, A., Steinberg, S. M., Lamble, A. J., Sheppard, J., Yates, B., Kovach, A. E., Wood, B., Borowitz, M. J., Stetler-Stevenson, M., Yuan, C. M., Pillai, V., Foley, T., Chung, P., Chen, L., Lee, D. W., Annesley, C., DiNofia, A., Grupp, S. A., . . . Shah, N. N. (2022). Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL. Journal of Clinical Oncology, 40(9), 932–944. https://doi.org/10.1200/jco.21.01405

96.

Yan, Z., Zhang, H., Cao, J., Zhang, C., Liu, H., Huang, H., Cheng, H., Qiao, J., Wang, Y., Wang, Y., Gao, L., Shi, M., Sang, W., Zhu, F., Li, D., Sun, H., Wu, Q., Qi, Y., Li, H., . . . Xu, K. (2021). Characteristics and risk factors of cytokine release syndrome in chimeric antigen receptor T cell treatment. Front Immunology, 12, 611366. https://doi.org/10.3389/fimmu.2021.611366

97.

Park, J. H., Rivière, I., Gonen, M., Wang, X., Sénéchal, B., Curran, K. J., Sauter, C., Wang, Y., Santomasso, B., Mead, E., Roshal, M., Maslak, P., Davila, M., Brentjens, R. J., & Sadelain, M. (2018). Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. New England Journal of Medicine, 378(5), 449–459. https://doi.org/10.1056/NEJMoa1709919CrossRefPubMed

98.

Silbert, S. K., Madan, S., Holland, E. M., Steinberg, S. M., Little, L., Foley, T., Epstein, M., Sarkisian, A., Lee, D. W., Nikitina, E., Kakumanu, S., Ruppin, E., Shalabi, H., Yates, B., & Shah, N. N. (2023). A comprehensive analysis of adverse events in the first 30 days of phase 1 pediatric CAR T-cell trials. Blood Advances, 7(18), 5566–5578. https://doi.org/10.1182/bloodadvances.2023009789CrossRefPubMedPubMedCentral

99.

Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., Cross, J. R., Liu, H., Vachha, B., Chen, X., DeAngelis, L. M., Li, D., Bernal, Y., Gonen, M., Wendel, H. G., . . . Brentjens, R. J. (2018). Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia. Cancer Discovery, 8(8), 958–971. https://doi.org/10.1158/2159-8290.Cd-17-1319

100.

Fabrizio, V. A., Phillips, C. L., Lane, A., Baggott, C., Prabhu, S., Egeler, E., Mavroukakis, S., Pacenta, H., Rossoff, J., Stefanski, H. E., Talano, J. A., Moskop, A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M., . . . Schultz, L. M. (2022). Tisagenlecleucel outcomes in relapsed/refractory extramedullary ALL: A Pediatric Real World CAR Consortium report. Blood Advances, 6(2), 600–610. https://doi.org/10.1182/bloodadvances.2021005564

101.

Holland, E. M., Yates, B., Ling, A., Yuan, C. M., Wang, H. W., Stetler-Stevenson, M., LaLoggia, M., Molina, J. C., Lichtenstein, D. A., Lee, D. W., Ligon, J. A., Shalabi, H., Ahlman, M. A., & Shah, N. N. (2022). Characterization of extramedullary disease in B-ALL and response to CAR T-cell therapy. Blood Advances, 6(7), 2167–2182. https://doi.org/10.1182/bloodadvances.2021006035CrossRefPubMedPubMedCentral

102.

Hay, K. A., Gauthier, J., Hirayama, A. V., Voutsinas, J. M., Wu, Q., Li, D., Gooley, T. A., Cherian, S., Chen, X., Pender, B. S., Hawkins, R. M., Vakil, A., Steinmetz, R. N., Schoch, G., Chapuis, A. G., Till, B. G., Kiem, H. P., Ramos, J. D., Shadman, M., . . . Turtle, C. J. (2019). Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 133(15), 1652–1663. https://doi.org/10.1182/blood-2018-11-883710

103.

Leahy, A. B., Newman, H., Li, Y., Liu, H., Myers, R., DiNofia, A., Dolan, J. G., Callahan, C., Baniewicz, D., Devine, K., Wray, L., Aplenc, R., June, C. H., Grupp, S. A., Rheingold, S. R., & Maude, S. L. (2021). CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: A post-hoc analysis of pooled data from five clinical trials. The Lancet Haematology, 8(10), e711–e722. https://doi.org/10.1016/s2352-3026(21)00238-6CrossRefPubMedPubMedCentral

104.

Jacoby, E., Ghorashian, S., Vormoor, B., De Moerloose, B., Bodmer, N., Molostova, O., Yanir, A. D., Buechner, J., Elhasid, R., Bielorai, B., Rogosic, S., Dourthe, M. E., Maschan, M., Rossig, C., Toren, A., von Stackelberg, A., Locatelli, F., Bader, P., Zimmermann, M., . . . Baruchel, A. (2022). CD19 CAR T-cells for pediatric relapsed acute lymphoblastic leukemia with active CNS involvement: A retrospective international study. Leukemia, 36(6), 1525–1532. https://doi.org/10.1038/s41375-022-01546-9

105.

Qi, Y., Zhao, M., Hu, Y., Wang, Y., Li, P., Cao, J., Shi, M., Tan, J., Zhang, M., Xiao, X., Xia, J., Ma, S., Qiao, J., Yan, Z., Li, H., Pan, B., Sang, W., Li, D., Li, Z., . . . Xu, K. (2022). Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSL. Blood, 139(23), 3376–3386. https://doi.org/10.1182/blood.2021013733

106.

Pennisi, M., Sanchez-Escamilla, M., Flynn, J. R., Shouval, R., Alarcon Tomas, A., Silverberg, M. L., Batlevi, C., Brentjens, R. J., Dahi, P. B., Devlin, S. M., Diamonte, C., Giralt, S., Halton, E. F., Jain, T., Maloy, M., Mead, E., Palomba, M. L., Ruiz, J., Santomasso, B., . . . Perales, M. A. (2021). Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. Blood Advances, 5(17), 3397–3406. https://doi.org/10.1182/bloodadvances.2020003885

107.

Rejeski, K., Perez, A., Sesques, P., Hoster, E., Berger, C., Jentzsch, L., Mougiakakos, D., Frölich, L., Ackermann, J., Bücklein, V., Blumenberg, V., Schmidt, C., Jallades, L., Fehse, B., Faul, C., Karschnia, P., Weigert, O., Dreyling, M., Locke, F. L., . . . Subklewe, M. (2021). CAR-HEMATOTOX: A model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood, 138(24), 2499–2513. https://doi.org/10.1182/blood.2020010543

108.

Rejeski, K., Wang, Y., Albanyan, O., Munoz, J., Sesques, P., Iacoboni, G., Lopez-Corral, L., Ries, I., Bücklein, V. L., Mohty, R., Dreyling, M., Baluch, A., Shah, B., Locke, F. L., Hess, G., Barba, P., Bachy, E., Lin, Y., Subklewe, M., & Jain, M. D. (2023). The CAR-`HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. American Journal of Hematology, 98(11), 1699–1710. https://doi.org/10.1002/ajh.27056CrossRefPubMedPubMedCentral

109.

Shah, N. N., Highfill, S. L., Shalabi, H., Yates, B., Jin, J., Wolters, P. L., Ombrello, A., Steinberg, S. M., Martin, S., Delbrook, C., Hoffman, L., Little, L., Ponduri, A., Qin, H., Qureshi, H., Dulau-Florea, A., Salem, D., Wang, H. W., Yuan, C., . . . Fry, T. J. (2020). CD4/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: Updated results from a phase I anti-CD22 CAR T-cell trial. Journal of Clinical Oncology, 38(17), 1938–1950. https://doi.org/10.1200/jco.19.03279

110.

Smith, R., & Shen, R. (2023). Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality. Journal of Translational Medicine, 21(1), 515. https://doi.org/10.1186/s12967-023-04372-4CrossRefPubMedPubMedCentral

111.

Johnson, P. C., Neckermann, I., Sadrzadeh, H., Newcomb, R., El-Jawahri, A. R., & Frigault, M. J. (2024). Clinical outcomes and toxicity in older adults receiving chimeric antigen receptor T cell therapy. Transplantation and Cellular Therapy, 30(5), 490–499. https://doi.org/10.1016/j.jtct.2024.02.019CrossRefPubMed

112.

Dreger, P., Holtick, U., Subklewe, M., von Tresckow, B., Ayuk, F., Wagner, E., Wulf, G., Marks, R., Penack, O., Schnetzke, U., Koenecke, C., von Bonin, M., Stelljes, M., Glass, B., Baldus, C. D., Vucinic, V., Mougiakakos, D., Topp, M., Schroers, R., . . . Bethge, W. A. (2023). Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: The GLA/DRST experience. Bone Marrow Transplant, 58(2), 229–232. https://doi.org/10.1038/s41409-022-01867-4

113.

Ghorashian, S., Jacoby, E., De Moerloose, B., Rives, S., Bonney, D., Shenton, G., Bader, P., Bodmer, N., Quintana, A. M., Herrero, B., Algeri, M., Locatelli, F., Vettenranta, K., Gonzalez, B., Attarbaschi, A., Harris, S., Bourquin, J. P., & Baruchel, A. (2022). Tisagenlecleucel therapy for relapsed or refractory B-cell acute lymphoblastic leukaemia in infants and children younger than 3 years of age at screening: An international, multicentre, retrospective cohort study. The Lancet Haematology, 9(10), e766–e775. https://doi.org/10.1016/s2352-3026(22)00225-3CrossRefPubMed

114.

Moskop, A., Pommert, L., Baggott, C., Prabhu, S., Pacenta, H. L., Phillips, C. L., Rossoff, J., Stefanski, H. E., Talano, J. A., Margossian, S. P., Verneris, M. R., Myers, G. D., Karras, N. A., Brown, P. A., Qayed, M., Hermiston, M. L., Satwani, P., Krupski, C., Keating, A. K., . . . Schultz, L. M. (2022). Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia. Blood Advances, 6(14), 4251–4255. https://doi.org/10.1182/bloodadvances.2021006393

115.

Faruqi, A. J., Ligon, J. A., Borgman, P., Steinberg, S. M., Foley, T., Little, L., Mackall, C. L., Lee, D. W., Fry, T. J., Shalabi, H., Brudno, J., Yates, B., Mikkilineni, L., Kochenderfer, J., & Shah, N. N. (2022). The impact of race, ethnicity, and obesity on CAR T-cell therapy outcomes. Blood Advances, 6(23), 6040–6050. https://doi.org/10.1182/bloodadvances.2022007676CrossRefPubMedPubMedCentral

116.

Orgel, E., Framson, C., Buxton, R., Kim, J., Li, G., Tucci, J., Freyer, D. R., Sun, W., Oberley, M. J., Dieli-Conwright, C., & Mittelman, S. D. (2021). Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: The IDEAL trial. Blood Advances, 5(7), 1853–1861. https://doi.org/10.1182/bloodadvances.2020004018CrossRefPubMedPubMedCentral

117.

Butturini, A. M., Dorey, F. J., Lange, B. J., Henry, D. W., Gaynon, P. S., Fu, C., Franklin, J., Siegel, S. E., Seibel, N. L., Rogers, P. C., Sather, H., Trigg, M., Bleyer, W. A., & Carroll, W. L. (2007). Obesity and outcome in pediatric acute lymphoblastic leukemia. Journal of Clinical Oncology, 25(15), 2063–2069. https://doi.org/10.1200/jco.2006.07.7792CrossRefPubMed

118.

Leo, Q. J., Ollberding, N. J., Wilkens, L. R., Kolonel, L. N., Henderson, B. E., Le Marchand, L., & Maskarinec, G. (2014). Obesity and non-Hodgkin lymphoma survival in an ethnically diverse population: The Multiethnic Cohort study. Cancer Causes and Control, 25(11), 1449–1459. https://doi.org/10.1007/s10552-014-0447-6CrossRefPubMed

119.

Wudhikarn, K., Bansal, R., Khurana, A., Hathcock, M. A., Bennani, N. N., Paludo, J., Villasboas, J. C., Wang, Y., Johnston, P. B., Ansell, S. M., & Lin, Y. (2021). The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. Blood Cancer Journal, 11(7), 124. https://doi.org/10.1038/s41408-021-00515-2CrossRefPubMedPubMedCentral

120.

Sorror, M. L., Maris, M. B., Storb, R., Baron, F., Sandmaier, B. M., Maloney, D. G., & Storer, B. (2005). Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood, 106(8), 2912–2919. https://doi.org/10.1182/blood-2005-05-2004CrossRefPubMedPubMedCentral

121.

Sorror, M. L., Logan, B. R., Zhu, X., Rizzo, J. D., Cooke, K. R., McCarthy, P. L., Ho, V. T., Horowitz, M. M., & Pasquini, M. C. (2015). Prospective validation of the predictive power of the hematopoietic cell transplantation comorbidity index: A Center for International Blood and Marrow Transplant Research study. Biology of Blood and Marrow Transplantation, 21(8), 1479–1487. https://doi.org/10.1016/j.bbmt.2015.04.004CrossRefPubMedPubMedCentral

122.

Silbert, S. K., Sarkisian, A., Steinberg, S. M., Yates, B., & Shah, N. N. (2023). 248 - Evaluating the prognostic utility of the hematopoietic cell transplantation comorbidity index (HCT-CI) in children and young adults with relapsed refractory B-cell acute lymphoblastic leukemia (r/r B-ALL) prior to CAR T-cell therapy. Transplantation and Cellular Therapy, 29(2, Supplement), S191. https://doi.org/10.1016/S2666-6367(23)00317-2CrossRef

123.

Greenbaum, U., Hashmi, H., Elsawy, M., Kim, S., Moskop, A., Awan, F. T., Farooq, U., Ganguly, S., Hematti, P., Jain, M. D., Kebriaei, P., Locke, F. L., Mead, E., Nishihori, T., Olson, A. L., Pennisi, M., Perales, M.-A., Ramakrishnan Geethakumari, P., Shouval, R., . . . Sorror, M. (2022). Prognostic impact of comorbidities on outcomes of patients (pts) with relapsed or refractory large B-cell lymphoma (r/r LBCL) treated with chimeric antigen receptor T-cell therapy (CART). Blood, 140(Supplement 1), 4636–4638. https://doi.org/10.1182/blood-2022-169452

124.

Shouse, G., Kaempf, A., Gordon, M. J., Artz, A., Yashar, D., Sigmund, A. M., Smilnak, G., Bair, S. M., Mian, A., Fitzgerald, L. A., Bajwa, A., Jaglowski, S., Bailey, N., Shadman, M., Patel, K., Stephens, D. M., Kamdar, M., Hill, B. T., Gauthier, J., . . . Danilov, A. V. (2023). A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. Blood Advances, 7(14), 3516–3529. https://doi.org/10.1182/bloodadvances.2022009309

125.

Rejeski, K., Perez, A., Iacoboni, G., Penack, O., Bücklein, V., Jentzsch, L., Mougiakakos, D., Johnson, G., Arciola, B., Carpio, C., Blumenberg, V., Hoster, E., Bullinger, L., Locke, F. L., von Bergwelt-Baildon, M., Mackensen, A., Bethge, W., Barba, P., Jain, M. D., & Subklewe, M. (2022). The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. Journal for Immunotherapy of Cancer, 10(5), e004475. https://doi.org/10.1136/jitc-2021-004475CrossRefPubMedPubMedCentral

126.

Jaggers, J. L., Giri, S., Klepin, H. D., Wildes, T. M., Olin, R. L., Artz, A., Wall, S., Jaglowski, S., William, B., Benson, D. M., & Rosko, A. E. (2021). Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. Journal of Geriatric Oncology, 12(2), 235–238. https://doi.org/10.1016/j.jgo.2020.08.004CrossRefPubMed

127.

Valade, S., Darmon, M., Zafrani, L., Mariotte, E., Lemiale, V., Bredin, S., Dumas, G., Boissel, N., Rabian, F., Baruchel, A., Madelaine, I., Larghero, J., Brignier, A., Lengliné, E., Harel, S., Arnulf, B., Di Blasi, R., Thieblemont, C., & Azoulay, E. (2022). The use of ICU resources in CAR-T cell recipients: A hospital-wide study. Annals of Intensive Care, 12(1), 75. https://doi.org/10.1186/s13613-022-01036-2CrossRefPubMedPubMedCentral

128.

Gutierrez, C., Neilan, T. G., & Grover, N. S. (2023). How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy. Blood, 141(20), 2452–2459. https://doi.org/10.1182/blood.2022017579CrossRefPubMedPubMedCentral

129.

Goldman, A., Maor, E., Bomze, D., Liu, J. E., Herrmann, J., Fein, J., Steingart, R. M., Mahmood, S. S., Schaffer, W. L., Perales, M. A., & Shouval, R. (2021). Adverse cardiovascular and pulmonary events associated with chimeric antigen receptor T-cell therapy. Journal of the American College of Cardiology, 78(18), 1800–1813. https://doi.org/10.1016/j.jacc.2021.08.044CrossRefPubMedPubMedCentral

130.

Ragoonanan, D., Bhar, S., Mohan, G., Beltramo, F., Khazal, S. J., Hurley, C., Andersen, C., Margossian, S., Neelapu, S. S., Shpall, E., Gutierrez, C., Tewari, P., Shoberu, B., Talleur, A., McCall, D., Nunez, C., Cuglievan, B., Tambaro, F. P., Petropoulos, D., . . . Mahadeo, K. M. (2022). A multicenter study of ICU resource utilization in pediatric, adolescent and young adult patients post CAR-T therapy. Frontiers in Oncology, 12, 1022901. https://doi.org/10.3389/fonc.2022.1022901

131.

Fitzgerald, J. C., Weiss, S. L., Maude, S. L., Barrett, D. M., Lacey, S. F., Melenhorst, J. J., Shaw, P., Berg, R. A., June, C. H., Porter, D. L., Frey, N. V., Grupp, S. A., & Teachey, D. T. (2017). Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Critical Care Medicine, 45(2), e124–e131. https://doi.org/10.1097/ccm.0000000000002053CrossRefPubMed

132.

Azoulay, E., Shimabukuro-Vornhagen, A., Darmon, M., & von Bergwelt-Baildon, M. (2019). Critical care management of chimeric antigen receptor T cell-related toxicity. Be aware and prepared. American Journal of Respiratory and Critical Care Medicine, 200(1), 20–23. https://doi.org/10.1164/rccm.201810-1945ED

133.

Azoulay, É., Castro, P., Maamar, A., Metaxa, V., de Moraes, A. G., Voigt, L., Wallet, F., Klouche, K., Picard, M., Moreau, A. S., Van De Louw, A., Seguin, A., Mokart, D., Chawla, S., Leroy, J., Böll, B., Issa, N., Levy, B., Hemelaar, P., . . . Valade, S. (2021). Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): An international, multicentre, observational cohort study. Lancet Haematology, 8(5), e355-e364. https://doi.org/10.1016/s2352-3026(21)00060-0

134.

Le Cacheux, C., Couturier, A., Sortais, C., Houot, R., Péré, M., Gastinne, T., Seguin, A., Reignier, J., Lascarrou, J. B., Tadié, J. M., Quelven, Q., & Canet, E. (2024). Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: A French multicentre cohort. Annals of Intensive Care, 14(1), 20. https://doi.org/10.1186/s13613-024-01247-9CrossRefPubMedPubMedCentral

135.

De Philippis, C., Mannina, D., Giordano, L., Costantini, E., Marcheselli, S., Mariotti, J., Sarina, B., Taurino, D., Santoro, A., & Bramanti, S. (2023). Impact of preemptive use of tocilizumab on chimeric antigen receptor T cell outcomes in non-Hodgkin lymphoma. Transplantation and Cellular Therapy, 29(7), 429.e421-429.e426. https://doi.org/10.1016/j.jtct.2023.03.019CrossRef

136.

Gutierrez, C., Brown, A. R. T., Herr, M. M., Kadri, S. S., Hill, B., Rajendram, P., Duggal, A., Turtle, C. J., Patel, K., Lin, Y., May, H. P., Gallo de Moraes, A., Maus, M. V., Frigault, M. J., Brudno, J. N., Athale, J., Shah, N. N., Kochenderfer, J. N., Dharshan, A., . . . Pastores, S. M. (2020). The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities. Journal of Critical Care, 58, 58–64. https://doi.org/10.1016/j.jcrc.2020.04.008

137.

Rathi, N. K., Haque, S. A., Nates, R., Kosturakis, A., Wang, H., Dong, W., Feng, L., Erfe, R. J., Guajardo, C., Withers, L., Finch, C., Price, K. J., & Nates, J. L. (2017). Noninvasivepositive pressure ventilation vsinvasive mechanical ventilation as first-line therapy for acute hypoxemic respiratory failure in cancer patients. Journal of Critical Care, 39, 56–61. https://doi.org/10.1016/j.jcrc.2017.01.007CrossRefPubMed

138.

Squadrone, V., Massaia, M., Bruno, B., Marmont, F., Falda, M., Bagna, C., Bertone, S., Filippini, C., Slutsky, A. S., Vitolo, U., Boccadoro, M., & Ranieri, V. M. (2010). Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. Intensive Care Medicine, 36(10), 1666–1674. https://doi.org/10.1007/s00134-010-1934-1CrossRefPubMed

139.

Ruff, M. W., Siegler, E. L., & Kenderian, S. S. (2020). A concise review of neurologic complications associated with chimeric antigen receptor T-cell immunotherapy. Neurologic Clinics, 38(4), 953–963. https://doi.org/10.1016/j.ncl.2020.08.001CrossRefPubMed

140.

Oddo, M., Crippa, I. A., Mehta, S., Menon, D., Payen, J. F., Taccone, F. S., & Citerio, G. (2016). Optimizing sedation in patients with acute brain injury. Critical Care, 20(1), 128. https://doi.org/10.1186/s13054-016-1294-5CrossRefPubMedPubMedCentral

141.

Mahadeo, K. M., Khazal, S. J., Abdel-Azim, H., Fitzgerald, J. C., Taraseviciute, A., Bollard, C. M., Tewari, P., Duncan, C., Traube, C., McCall, D., Steiner, M. E., Cheifetz, I. M., Lehmann, L. E., Mejia, R., Slopis, J. M., Bajwa, R., Kebriaei, P., Martin, P. L., Moffet, J., . . . Shpall, E. J. (2019). Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nature Reviews Clinical Oncology, 16(1), 45–63. https://doi.org/10.1038/s41571-018-0075-2

142.

Brown, B. D., Tambaro, F. P., Kohorst, M., Chi, L., Mahadeo, K. M., Tewari, P., Petropoulos, D., Slopis, J. M., Sadighi, Z., & Khazal, S. (2021). Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: Can we optimize early diagnosis? Frontiers in Oncology, 11, 634445. https://doi.org/10.3389/fonc.2021.634445CrossRefPubMedPubMedCentral

143.

Shalabi, H., Wolters, P. L., Martin, S., Toledo-Tamula, M. A., Roderick, M. C., Struemph, K., Kane, E., Yates, B., Delbrook, C., Mackall, C. L., Lee, D. W., Fry, T. J., & Shah, N. N. (2018). Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy. Journal of Immunotherapy, 41(7), 350–358. https://doi.org/10.1097/cji.0000000000000241CrossRefPubMed

144.

Power, N., & Franck, L. (2008). Parent participation in the care of hospitalized children: A systematic review. Journal of Advanced Nursing, 62(6), 622–641. https://doi.org/10.1111/j.1365-2648.2008.04643.xCrossRefPubMed

145.

McNerney, K. O., Hsieh, E. M., Shalabi, H., Epperly, R., Wolters, P. L., Hill, J. A., Gardner, R., Talleur, A. C., Shah, N. N., & Rossoff, J. (2024). INSPIRED Symposium part 3: Prevention and management of pediatric chimeric antigen receptor T cell-associated emergent toxicities. Transplant Cell Ther, 30(1), 38–55. https://doi.org/10.1016/j.jtct.2023.10.006CrossRefPubMed

146.

Stenson, C. L., Vidrine, J., Dewhurst, F., Osborne, W., Menne, T., & Stocker, R. (2023). A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: Recommendations for service development and implications for palliative care teams. Palliative Medicine, 37(2), 215–220. https://doi.org/10.1177/02692163221138880CrossRefPubMed

147.

Efficace, F., Cannella, L., Sparano, F., Giesinger, J. M., Vignetti, M., Baron, F., Bruera, E., Luppi, M., & Platzbecker, U. (2022). Chimeric antigen receptor T-cell therapy in hematologic malignancies and patient-reported outcomes: A scoping review. Hemasphere, 6(12), e802. https://doi.org/10.1097/hs9.0000000000000802CrossRefPubMedPubMedCentral

148.

Johnson, P. C., Dhawale, T., Newcomb, R. A., Amonoo, H. L., Lavoie, M. W., Vaughn, D., Karpinski, K., & El-Jawahri, A. (2023). Longitudinal patient-reported outcomes in patients receiving chimeric antigen receptor T-cell therapy. Blood Advances, 7(14), 3541–3550. https://doi.org/10.1182/bloodadvances.2022009117CrossRefPubMedPubMedCentral

149.

Wang, X. S., Srour, S. A., Whisenant, M., Subbiah, I. M., Chen, T. H., Ponce, D., Gonzalez, A. G., Kamal, M., Mendoza, T., Cleland, C. S., Kebriaei, P., Neelapu, S. S., Rezvani, K., Ahmed, S., & Shpall, E. (2021). Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies. Transplant Cell Ther, 27(11), 930.e931-930.e910. https://doi.org/10.1016/j.jtct.2021.07.007CrossRef

150.

Sidana, S., Dueck, A. C., Thanarajasingam, G., Griffin, J. M., Thompson, C., Durani, U., Burtis, M., Warsame, R., Paludo, J., Gertz, M. A., Dispenzieri, A., Ansell, S. M., Rajkumar, S. V., Yost, K., Bennani, N., Lin, Y., & Kumar, S. (2022). Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant. Transplantation and Cellular Therapy, 28(8), 473–482. https://doi.org/10.1016/j.jtct.2022.05.004CrossRefPubMedPubMedCentral

151.

Wang, X. S., Srour, S. A., Mendoza, T., Whisenant, M., Subbiah, I., Gonzalez, E., Kamal, M., Shen, S. E., Cleeland, C., Kebriaei, P., Rezvani, K., Neelapu, S., Ahmed, S., & Shpall, E. (2023). Development and validation of a patient-reported outcome measure to assess symptom burden after chimeric antigen receptor T-cell therapy. British Journal of Haematology, 201(4), 738–746. https://doi.org/10.1111/bjh.18677CrossRefPubMedPubMedCentral

152.

Laetsch, T. W., Myers, G. D., Baruchel, A., Dietz, A. C., Pulsipher, M. A., Bittencourt, H., Buechner, J., De Moerloose, B., Davis, K. L., Nemecek, E., Driscoll, T., Mechinaud, F., Boissel, N., Rives, S., Bader, P., Peters, C., Sabnis, H. S., Grupp, S. A., Yanik, G. A., . . . Harris, A. C. (2019). Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: A global, single-arm, phase 2 trial. The Lancet Oncology, 20(12), 1710–1718. https://doi.org/10.1016/s1470-2045(19)30493-0

153.

Tschernia, N. P., Heiling, H., Deal, A. M., Cheng, C., Babinec, C., Gonzalez, M., Morrison, J. K., Dittus, C., Dotti, G., Beaven, A. W., Serody, J. S., Wood, W. A., Savoldo, B., & Grover, N. S. (2023). Patient-reported outcomes in CD30-directed CAR-T cells against relapsed/refractory CD30+ lymphomas. Journal for Immunotherapy of Cancer, 11(8), e006959. https://doi.org/10.1136/jitc-2023-006959CrossRefPubMedPubMedCentral

154.

Barata, A., Dhawale, T., Newcomb, R. A., Amonoo, H. L., Nelson, A. M., Yang, D., Karpinski, K., Holmbeck, K., Farnam, E., Frigault, M., Johnson, P. C., & El-Jawahri, A. (2024). Quality of life and prognostic awareness in caregivers of patients receiving chimeric antigen receptor T cell therapy. Transplantation and Cellular Therapy, 30(4), 452.e451-452.e411. https://doi.org/10.1016/j.jtct.2024.01.063CrossRef

155.

Wolfe, J., Orellana, L., Cook, E. F., Ullrich, C., Kang, T., Geyer, J. R., Feudtner, C., Weeks, J. C., & Dussel, V. (2014). Improving the care of children with advanced cancer by using an electronic patient-reported feedback intervention: Results from the PediQUEST randomized controlled trial. Journal of Clinical Oncology, 32(11), 1119–1126. https://doi.org/10.1200/jco.2013.51.5981CrossRefPubMedPubMedCentral

156.

Lai, J. S., Jensen, S. E., Peipert, J. D., Mitchell, S. A., Garcia, S. F., Cella, D., Goldman, S., & Lenzen, A. (2023). Using IT to improve outcomes for children living with cancer (SyMon-SAYS): Protocol for a single-institution waitlist randomized controlled trial. JMIR Research Protocols, 12, e50993. https://doi.org/10.2196/50993CrossRefPubMedPubMedCentral

157.

Velikova, G., Absolom, K., Hewison, J., Holch, P., Warrington, L., Avery, K., Richards, H., Blazeby, J., Dawkins, B., Hulme, C., Carter, R., Glidewell, L., Henry, A., Franks, K., Hall, G., Davidson, S., Henry, K., Morris, C., Conner, M., . . . Brown, J. (2022). Programme grants for applied research. In Electronic self-reporting of adverse events for patients undergoing cancer treatment: The eRAPID research programme including two RCTs. NIHR Journals Library. Copyright © 2022 Velikova et al. This work was produced by Velikova et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This is an Open Access publication distributed under the terms of the Creative Commons Attribution CC BY 4.0 licence, which permits unrestricted use, distribution, reproduction and adaption in any medium and for any purpose provided that it is properly attributed. See: https://creativecommons.org/licenses/by/4.0/. For attribution the title, original author(s), the publication source – NIHR Journals Library, and the DOI of the publication must be cited. https://doi.org/10.3310/fdde8516

158.

Steineck, A., Wiener, L., Mack, J. W., Shah, N. N., Summers, C., & Rosenberg, A. R. (2020). Psychosocial care for children receiving chimeric antigen receptor (CAR) T-cell therapy. Pediatric Blood & Cancer, 67(5), e28249. https://doi.org/10.1002/pbc.28249CrossRef

159.

Springell, D., O’Reilly, M., & Roddie, C. (2023). Supportive care for chimeric antigen receptor T-cell patients. Current Opinion in Supportive and Palliative Care, 17(3), 231–239. https://doi.org/10.1097/spc.0000000000000657CrossRefPubMed

160.

Cliff, E. R. S., Kelkar, A. H., Russler-Germain, D. A., Tessema, F. A., Raymakers, A. J. N., Feldman, W. B., & Kesselheim, A. S. (2023). High cost of chimeric antigen receptor T-cells: Challenges and solutions. American Society of Clinical Oncology Educational Book, 43, e397912. https://doi.org/10.1200/edbk_397912CrossRefPubMed

161.

Hoover, A., Reimche, P., Watson, D., Tanner, L., Gilchrist, L., Finch, M., Messinger, Y. H., & Turcotte, L. M. (2024). Healthcare cost and utilization for chimeric antigen receptor (CAR) T-cell therapy in the treatment of pediatric acute lymphoblastic leukemia: A commercial insurance claims database analysis. Cancer Rep (Hoboken), 7(2), e1980. https://doi.org/10.1002/cnr2.1980CrossRefPubMed

162.

Ahmed, N., Shahzad, M., Shippey, E., Bansal, R., Mushtaq, M. U., Mahmoudjafari, Z., Faisal, M. S., Hoffmann, M., Abdallah, A. O., Divine, C., Hamadani, M., McGuirk, J., & Shune, L. (2022). Socioeconomic and racial disparity in chimeric antigen receptor T cell therapy access. Transplantation and Cellular Therapy, 28(7), 358–364. https://doi.org/10.1016/j.jtct.2022.04.008CrossRefPubMed

163.

Mallapaty, S. (2024). Cutting-edge CAR-T cancer therapy is now made in India - At one-tenth the cost. Nature, 627(8005), 709–710. https://doi.org/10.1038/d41586-024-00809-yCrossRefPubMed

164.

Palani, H. K., Arunachalam, A. K., Yasar, M., Venkatraman, A., Kulkarni, U., Lionel, S. A., Selvarajan, S., Korula, A., Abraham, A., George, B., Adair, J. E., Orentas, R., Dropulic, B., & Mathews, V. (2023). Decentralized manufacturing of anti CD19 CAR-T cells using CliniMACS Prodigy®: Real-world experience and cost analysis in India. Bone Marrow Transplantation, 58(2), 160–167. https://doi.org/10.1038/s41409-022-01866-5CrossRefPubMed

165.

Juillerat, A., Tkach, D., Busser, B. W., Temburni, S., Valton, J., Duclert, A., Poirot, L., Depil, S., & Duchateau, P. (2019). Modulation of chimeric antigen receptor surface expression by a small molecule switch. BMC Biotechnology, 19(1), 44. https://doi.org/10.1186/s12896-019-0537-3CrossRefPubMedPubMedCentral

166.

Wu, C. Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015). Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science, 350(6258), aab4077. https://doi.org/10.1126/science.aab4077CrossRefPubMedPubMedCentral

167.

Juillerat, A., Marechal, A., Filhol, J. M., Valton, J., Duclert, A., Poirot, L., & Duchateau, P. (2016). Design of chimeric antigen receptors with integrated controllable transient functions. Science and Reports, 6, 18950. https://doi.org/10.1038/srep18950CrossRef

168.

Appelbaum, J., Price, A. E., Oda, K., Zhang, J., Leung, W. H., Tampella, G., Xia, D., So, P. P., Hilton, S. K., Evandy, C., Sarkar, S., Martin, U., Krostag, A. R., Leonardi, M., Zak, D. E., Logan, R., Lewis, P., Franke-Welch, S., Ngwenyama, N., . . . Jensen, M. C. (2024). Drug-regulated CD33-targeted CAR T cells control AML using clinically optimized rapamycin dosing. Journal of Clinical Investigation, 134(9). https://doi.org/10.1172/jci162593

169.

Ying, Z., Huang, X. F., Xiang, X., Liu, Y., Kang, X., Song, Y., Guo, X., Liu, H., Ding, N., Zhang, T., Duan, P., Lin, Y., Zheng, W., Wang, X., Lin, N., Tu, M., Xie, Y., Zhang, C., Liu, W., . . . Chen, S. Y. (2019). A safe and potent anti-CD19 CAR T cell therapy. Nature Medicine, 25(6), 947–953. https://doi.org/10.1038/s41591-019-0421-7

170.

Fisher, J., & Anderson, J. (2018). Engineering approaches in human gamma delta T cells for cancer immunotherapy. Frontiers in Immunology, 9, 1409. https://doi.org/10.3389/fimmu.2018.01409CrossRefPubMedPubMedCentral

171.

Fisher, J., Abramowski, P., Wisidagamage Don, N. D., Flutter, B., Capsomidis, A., Cheung, G. W., Gustafsson, K., & Anderson, J. (2017). Avoidance of on-target off-tumor activation using a co-stimulation-only chimeric antigen receptor. Molecular Therapy, 25(5), 1234–1247. https://doi.org/10.1016/j.ymthe.2017.03.002CrossRefPubMedPubMedCentral

172.

Kim, M. Y., Yu, K. R., Kenderian, S. S., Ruella, M., Chen, S., Shin, T. H., Aljanahi, A. A., Schreeder, D., Klichinsky, M., Shestova, O., Kozlowski, M. S., Cummins, K. D., Shan, X., Shestov, M., Bagg, A., Morrissette, J. J. D., Sekhri, P., Lazzarotto, C. R., Calvo, K. R., . . . Gill, S. (2018). Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell, 173(6), 1439–1453.e1419. https://doi.org/10.1016/j.cell.2018.05.013

173.

Zhang, Q., Zhao, Y. Z., Ma, H. H., Wang, D., Cui, L., Li, W. J., Wei, A., Wang, C. J., Wang, T. Y., Li, Z. G., & Zhang, R. (2022). A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis. Blood, 139(24), 3493–3504. https://doi.org/10.1182/blood.2021014860CrossRefPubMed

174.

Wang, J., Wang, Y., Wu, L., Wang, X., Jin, Z., Gao, Z., & Wang, Z. (2020). Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica, 105(5), e210–e212. https://doi.org/10.3324/haematol.2019.222471CrossRefPubMedPubMedCentral

175.

Wang, J., Zhang, R., Wu, X., Li, F., Yang, H., Liu, L., Guo, H., Zhang, X., Mai, H., Li, H., & Wang, Z. (2021). Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: A single-arm, multicentre, phase 2 trial. British Journal of Haematology, 193(4), 761–768. https://doi.org/10.1111/bjh.17331CrossRefPubMed

176.

Bergsten, E., Horne, A., Aricó, M., Astigarraga, I., Egeler, R. M., Filipovich, A. H., Ishii, E., Janka, G., Ladisch, S., Lehmberg, K., McClain, K. L., Minkov, M., Montgomery, S., Nanduri, V., Rosso, D., & Henter, J. I. (2017). Confirmed efficacy of etoposide and dexamethasone in HLH treatment: Long-term results of the cooperative HLH-2004 study. Blood, 130(25), 2728–2738. https://doi.org/10.1182/blood-2017-06-788349CrossRefPubMedPubMedCentral

177.

Strati, P., Ahmed, S., Kebriaei, P., Nastoupil, L. J., Claussen, C. M., Watson, G., Horowitz, S. B., Brown, A. R. T., Do, B., Rodriguez, M. A., Nair, R., Shpall, E. J., Green, M. R., Neelapu, S. S., & Westin, J. R. (2020). Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma. Blood Advances, 4(13), 3123–3127. https://doi.org/10.1182/bloodadvances.2020002328CrossRefPubMedPubMedCentral

178.

Kenderian, S. S., Durrant, C., Chappell, D., Ahmed, O., & Kilcoyne, A. (2021). A phase 2/3 randomized, placebo-controlled, open-label, multi-center trial of lenzilumab to improve the safety and efficacy of CAR-T cell therapy in adults with relapsed or refractory large B-cell lymphoma (The SHIELD Study). Blood, 138(Supplement 1), 1758–1758. https://doi.org/10.1182/blood-2021-153987CrossRef

179.

Park, J. H., Nath, K., Devlin, S. M., Sauter, C. S., Palomba, M. L., Shah, G., Dahi, P., Lin, R. J., Scordo, M., Perales, M. A., Shouval, R., Tomas, A. A., Cathcart, E., Mead, E., Santomasso, B., Holodny, A., Brentjens, R. J., Riviere, I., & Sadelain, M. (2023). CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: Phase 2 trial interim results. Nature Medicine, 29(7), 1710–1717. https://doi.org/10.1038/s41591-023-02404-6CrossRefPubMedPubMedCentral

180.

Patel, S., Cenin, D., Corrigan, D., Hamilton, B. K., Kalaycio, M., Sobecks, R. M., Anwer, F., Khouri, J., Dean, R. M., Winter, A., Jagadeesh, D., Pohlman, B., Hill, B. T., Sauter, C. S., & Caimi, P. F. (2022). Siltuximab for first-line treatment of cytokine release syndrome: A response to the national shortage of tocilizumab. Blood, 140(Supplement 1), 5073–5074. https://doi.org/10.1182/blood-2022-169809CrossRef

181.

Bajwa, A. K., Zhao, Q., Geer, M. J., Mian, A., Lin, C., Frame, D., Westholder, J., Tossey, J., Ghosh, M., Galal, A., Ahmed, N., Maakaron, J. E., Denlinger, N., de Lima, M., Epperla, N., Caimi, P. F., & Voorhees, T. (2023). Efficacy of siltuximab for chimeric antigen receptor T-cell therapy toxicities - A multicenter retrospective analysis. Blood, 142(Supplement 1), 4502–4502. https://doi.org/10.1182/blood-2023-179620CrossRef

182.

Ito, M., Hiramatsu, H., Kobayashi, K., Suzue, K., Kawahata, M., Hioki, K., Ueyama, Y., Koyanagi, Y., Sugamura, K., Tsuji, K., Heike, T., & Nakahata, T. (2002). NOD/SCID/gamma(c)(null) mouse: An excellent recipient mouse model for engraftment of human cells. Blood, 100(9), 3175–3182. https://doi.org/10.1182/blood-2001-12-0207CrossRefPubMed

183.

Si, X., Xiao, L., Brown, C. E., & Wang, D. (2022). Preclinical evaluation of CAR T cell function: In vitro and in vivo models. International Journal of Molecular Sciences, 23(6), 3154. https://doi.org/10.3390/ijms23063154CrossRefPubMedPubMedCentral

184.

Duncan, B. B., Dunbar, C. E., & Ishii, K. (2022). Applying a clinical lens to animal models of CAR-T cell therapies. Molecular Therapy - Methods & Clinical Development, 27, 17–31. https://doi.org/10.1016/j.omtm.2022.08.008CrossRef

185.

van der Stegen, S. J., Davies, D. M., Wilkie, S., Foster, J., Sosabowski, J. K., Burnet, J., Whilding, L. M., Petrovic, R. M., Ghaem-Maghami, S., Mather, S., Jeannon, J. P., Parente-Pereira, A. C., & Maher, J. (2013). Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: Identifying a window of therapeutic opportunity? The Journal of Immunology, 191(9), 4589–4598. https://doi.org/10.4049/jimmunol.1301523CrossRefPubMed

186.

Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018). CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nature Medicine, 24(6), 731–738. https://doi.org/10.1038/s41591-018-0041-7CrossRefPubMedPubMedCentral

187.

Olson, B., Li, Y., Lin, Y., Liu, E. T., & Patnaik, A. (2018). Mouse models for cancer immunotherapy research. Cancer Discovery, 8(11), 1358–1365. https://doi.org/10.1158/2159-8290.Cd-18-0044CrossRefPubMedPubMedCentral

188.

Ishii, K., Pouzolles, M., Chien, C. D., Erwin-Cohen, R. A., Kohler, M. E., Qin, H., Lei, H., Kuhn, S., Ombrello, A. K., Dulau-Florea, A., Eckhaus, M. A., Shalabi, H., Yates, B., Lichtenstein, D. A., Zimmermann, V. S., Kondo, T., Shern, J. F., Young, H. A., Taylor, N., . . . Fry, T. J. (2020). Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients. Journal of Clinical Investigation, 130(10), 5425–5443. https://doi.org/10.1172/jci130059

189.

Pennell, C. A., Barnum, J. L., McDonald-Hyman, C. S., Panoskaltsis-Mortari, A., Riddle, M. J., Xiong, Z., Loschi, M., Thangavelu, G., Campbell, H. M., Storlie, M. D., Refaeli, Y., Furlan, S. N., Jensen, M. C., Kean, L. S., Miller, J. S., Tolar, J., Osborn, M. J., & Blazar, B. R. (2018). Human CD19-targeted mouse T cells induce B cell aplasia and toxicity in human CD19 transgenic mice. Molecular Therapy, 26(6), 1423–1434. https://doi.org/10.1016/j.ymthe.2018.04.006CrossRefPubMedPubMedCentral

190.

Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., Traversari, C., Bordignon, C., Ciceri, F., Ostuni, R., Bonini, C., Casucci, M., & Bondanza, A. (2018). Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nature Medicine, 24(6), 739–748. https://doi.org/10.1038/s41591-018-0036-4CrossRefPubMed

191.

Taraseviciute, A., Tkachev, V., Ponce, R., Turtle, C. J., Snyder, J. M., Liggitt, H. D., Myerson, D., Gonzalez-Cuyar, L., Baldessari, A., English, C., Yu, A., Zheng, H., Furlan, S. N., Hunt, D. J., Hoglund, V., Finney, O., Brakke, H., Blazar, B. R., Berger, C., . . . Jensen, M. C. (2018). Chimeric antigen receptor T cell-mediated neurotoxicity in nonhuman primates. Cancer Discovery, 8(6), 750–763. https://doi.org/10.1158/2159-8290.Cd-17-1368

192.

Berger, C., Sommermeyer, D., Hudecek, M., Berger, M., Balakrishnan, A., Paszkiewicz, P. J., Kosasih, P. L., Rader, C., & Riddell, S. R. (2015). Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells. Cancer Immunology Research, 3(2), 206–216. https://doi.org/10.1158/2326-6066.Cir-14-0163CrossRefPubMed

193.

Yagyu, S., Mochizuki, H., Yamashima, K., Kubo, H., Saito, S., Tanaka, M., Sakamoto, K., Shimoi, A., & Nakazawa, Y. (2021). A lymphodepleted non-human primate model for the assessment of acute on-target and off-tumor toxicity of human chimeric antigen receptor-T cells. Clin Transl Immunology, 10(6), e1291. https://doi.org/10.1002/cti2.1291CrossRefPubMedPubMedCentral

194.

Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020). Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nature Reviews Clinical Oncology, 17(3), 147–167. https://doi.org/10.1038/s41571-019-0297-yCrossRefPubMed

195.

Vander Mause, E. R., Atanackovic, D., Lim, C. S., & Luetkens, T. (2022). Roadmap to affinity-tuned antibodies for enhanced chimeric antigen receptor T cell function and selectivity. Trends in Biotechnology, 40(7), 875–890. https://doi.org/10.1016/j.tibtech.2021.12.009CrossRefPubMed

196.

Caruso, H. G., Hurton, L. V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., Lee, D. A., Heimberger, A. B., Champlin, R. E., & Cooper, L. J. (2015). Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent antitumor activity. Cancer Research, 75(17), 3505–3518. https://doi.org/10.1158/0008-5472.Can-15-0139CrossRefPubMedPubMedCentral

197.

Song, D. G., Ye, Q., Poussin, M., Liu, L., Figini, M., & Powell, D. J., Jr. (2015). A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity. Oncotarget, 6(25), 21533–21546. https://doi.org/10.18632/oncotarget.4071CrossRefPubMedPubMedCentral

198.

Liu, X., Jiang, S., Fang, C., Yang, S., Olalere, D., Pequignot, E. C., Cogdill, A. P., Li, N., Ramones, M., Granda, B., Zhou, L., Loew, A., Young, R. M., June, C. H., & Zhao, Y. (2015). Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice. Cancer Research, 75(17), 3596–3607. https://doi.org/10.1158/0008-5472.Can-15-0159CrossRefPubMedPubMedCentral

199.

Chmielewski, M., Hombach, A., Heuser, C., Adams, G. P., & Abken, H. (2004). T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity. The Journal of Immunology, 173(12), 7647–7653. https://doi.org/10.4049/jimmunol.173.12.7647CrossRefPubMed

200.

Ghorashian, S., Kramer, A. M., Onuoha, S., Wright, G., Bartram, J., Richardson, R., Albon, S. J., Casanovas-Company, J., Castro, F., Popova, B., Villanueva, K., Yeung, J., Vetharoy, W., Guvenel, A., Wawrzyniecka, P. A., Mekkaoui, L., Cheung, G. W., Pinner, D., Chu, J., . . . Amrolia, P. J. (2019). Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nature Medicine, 25(9), 1408–1414. https://doi.org/10.1038/s41591-019-0549-5

201.

Roddie, C., Dias, J., O'Reilly, M. A., Abbasian, M., Cadinanos-Garai, A., Vispute, K., Bosshard-Carter, L., Mitsikakou, M., Mehra, V., Roddy, H., Hartley, J. A., Spanswick, V., Lowe, H., Popova, B., Clifton-Hadley, L., Wheeler, G., Olejnik, J., Bloor, A., Irvine, D., . . . Peggs, K. S. (2021). Durable responses and low toxicity after fast off-rate CD19 chimeric antigen receptor-T therapy in adults with relapsed or refractory B-cell acute lymphoblastic leukemia. Journal of Clinical Oncology, 39(30), 3352–3363. https://doi.org/10.1200/jco.21.00917

202.

Zhang, Y., Patel, R. P., Kim, K. H., Cho, H., Jo, J. C., Jeong, S. H., Oh, S. Y., Choi, Y. S., Kim, S. H., Lee, J. H., Angelos, M., Guruprasad, P., Cohen, I., Ugwuanyi, O., Lee, Y. G., Pajarillo, R., Cho, J. H., Carturan, A., Paruzzo, L., . . . Ruella, M. (2023). Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: A first-in-human study. Molecular Cancer, 22(1), 200. https://doi.org/10.1186/s12943-023-01886-9

203.

Whilding, L. M., Halim, L., Draper, B., Parente-Pereira, A. C., Zabinski, T., Davies, D. M., & Maher, J. (2019). CAR T-cells targeting the integrin αvβ6 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers (Basel), 11(5), 674. https://doi.org/10.3390/cancers11050674CrossRefPubMed

204.

Hamieh, M., Mansilla-Soto, J., Rivière, I., & Sadelain, M. (2023). Programming CAR T cell tumor recognition: Tuned antigen sensing and logic gating. Cancer Discovery, 13(4), 829–843. https://doi.org/10.1158/2159-8290.Cd-23-0101CrossRefPubMedPubMedCentral

205.

Tousley, A. M., Rotiroti, M. C., Labanieh, L., Rysavy, L. W., Kim, W. J., Lareau, C., Sotillo, E., Weber, E. W., Rietberg, S. P., Dalton, G. N., Yin, Y., Klysz, D., Xu, P., de la Serna, E. L., Dunn, A. R., Satpathy, A. T., Mackall, C. L., & Majzner, R. G. (2023). Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature, 615(7952), 507–516. https://doi.org/10.1038/s41586-023-05778-2CrossRefPubMedPubMedCentral

206.

Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J., Jr. (2013). Chimeric antigen receptor T cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo. Cancer Immunology Research, 1(1), 43–53. https://doi.org/10.1158/2326-6066.Cir-13-0008CrossRefPubMedPubMedCentral

207.

Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013). Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells. Nature Biotechnology, 31(1), 71–75. https://doi.org/10.1038/nbt.2459CrossRefPubMed

208.

Wilkie, S., van Schalkwyk, M. C., Hobbs, S., Davies, D. M., van der Stegen, S. J., Pereira, A. C., Burbridge, S. E., Box, C., Eccles, S. A., & Maher, J. (2012). Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. Journal of Clinical Immunology, 32(5), 1059–1070. https://doi.org/10.1007/s10875-012-9689-9CrossRefPubMed

209.

Katsarou, A., Sjöstrand, M., Naik, J., Mansilla-Soto, J., Kefala, D., Kladis, G., Nianias, A., Ruiter, R., Poels, R., Sarkar, I., Patankar, Y. R., Merino, E., Reijmers, R. M., Frerichs, K. A., Yuan, H., de Bruijn, J., Stroopinsky, D., Avigan, D., van de Donk, N., . . . Themeli, M. (2021). Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence. Science Translational Medicine, 13(623), eabh1962. https://doi.org/10.1126/scitranslmed.abh1962

210.

Dao, T., Xiong, G., Mun, S. S., Meyerberg, J., Korontsvit, T., Xiang, J., Cui, Z., Chang, A. Y., Jarvis, C., Cai, W., Luo, H., Pierson, A., Daniyan, A., Yoo, S., Takao, S., Kharas, M., Kentsis, A., Liu, C., & Scheinberg, D. A. (2024). A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML. Blood, 143(6), 507–521. https://doi.org/10.1182/blood.2023021054CrossRefPubMed

211.

Roybal, K. T., Rupp, L. J., Morsut, L., Walker, W. J., McNally, K. A., Park, J. S., & Lim, W. A. (2016). Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell, 164(4), 770–779. https://doi.org/10.1016/j.cell.2016.01.011CrossRefPubMedPubMedCentral

212.

Srivastava, S., Salter, A. I., Liggitt, D., Yechan-Gunja, S., Sarvothama, M., Cooper, K., Smythe, K. S., Dudakov, J. A., Pierce, R. H., Rader, C., & Riddell, S. R. (2019). Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell, 35(3), 489-503.e488. https://doi.org/10.1016/j.ccell.2019.02.003CrossRefPubMedPubMedCentral

213.

Morsut, L., Roybal, K. T., Xiong, X., Gordley, R. M., Coyle, S. M., Thomson, M., & Lim, W. A. (2016). Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell, 164(4), 780–791. https://doi.org/10.1016/j.cell.2016.01.012CrossRefPubMedPubMedCentral

214.

Choe, J. H., Watchmaker, P. B., Simic, M. S., Gilbert, R. D., Li, A. W., Krasnow, N. A., Downey, K. M., Yu, W., Carrera, D. A., Celli, A., Cho, J., Briones, J. D., Duecker, J. M., Goretsky, Y. E., Dannenfelser, R., Cardarelli, L., Troyanskaya, O., Sidhu, S. S., Roybal, K. T., . . . Lim, W. A. (2021). SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Science Translational Medicine, 13(591). https://doi.org/10.1126/scitranslmed.abe7378

215.

Roybal, K. T., Williams, J. Z., Morsut, L., Rupp, L. J., Kolinko, I., Choe, J. H., Walker, W. J., McNally, K. A., & Lim, W. A. (2016). Engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell, 167(2), 419-432.e416. https://doi.org/10.1016/j.cell.2016.09.011CrossRefPubMedPubMedCentral

216.

Hyrenius-Wittsten, A., Su, Y., Park, M., Garcia, J. M., Alavi, J., Perry, N., Montgomery, G., Liu, B., & Roybal, K. T. (2021). SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Science Translational Medicine, 13(591), 8836. https://doi.org/10.1126/scitranslmed.abd8836CrossRef

217.

Richards, R. M., Zhao, F., Freitas, K. A., Parker, K. R., Xu, P., Fan, A., Sotillo, E., Daugaard, M., Oo, H. Z., Liu, J., Hong, W. J., Sorensen, P. H., Chang, H. Y., Satpathy, A. T., Majzner, R. G., Majeti, R., & Mackall, C. L. (2021). NOT-gated CD93 CAR T cells effectively target AML with minimized endothelial cross-reactivity. Blood Cancer Discovery, 2(6), 648–665. https://doi.org/10.1158/2643-3230.Bcd-20-0208CrossRefPubMedPubMedCentral

218.

Fedorov, V. D., Themeli, M., & Sadelain, M. (2013). PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Science Translational Medicine, 5(215), 215ra17. https://doi.org/10.1126/scitranslmed.3006597CrossRef

219.

Marin, V., Cribioli, E., Philip, B., Tettamanti, S., Pizzitola, I., Biondi, A., Biagi, E., & Pule, M. (2012). Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells. Hum Gene Ther Methods, 23(6), 376–386. https://doi.org/10.1089/hgtb.2012.050CrossRefPubMedPubMedCentral

220.

Sahillioglu, A. C., & Schumacher, T. N. (2022). Safety switches for adoptive cell therapy. Current Opinion in Immunology, 74, 190–198. https://doi.org/10.1016/j.coi.2021.07.002CrossRefPubMed

221.

Jones, B. S., Lamb, L. S., Goldman, F., & Di Stasi, A. (2014). Improving the safety of cell therapy products by suicide gene transfer. Frontiers in Pharmacology, 5, 254. https://doi.org/10.3389/fphar.2014.00254CrossRefPubMedPubMedCentral

222.

Serafini, M., Manganini, M., Borleri, G., Bonamino, M., Imberti, L., Biondi, A., Golay, J., Rambaldi, A., & Introna, M. (2004). Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease. Human Gene Therapy, 15(1), 63–76. https://doi.org/10.1089/10430340460732463CrossRefPubMed

223.

Griffioen, M., van Egmond, E. H., Kester, M. G., Willemze, R., Falkenburg, J. H., & Heemskerk, M. H. (2009). Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy. Haematologica, 94(9), 1316–1320. https://doi.org/10.3324/haematol.2008.001677CrossRefPubMedPubMedCentral

224.

Philip, B., Kokalaki, E., Mekkaoui, L., Thomas, S., Straathof, K., Flutter, B., Marin, V., Marafioti, T., Chakraverty, R., Linch, D., Quezada, S. A., Peggs, K. S., & Pule, M. (2014). A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood, 124(8), 1277–1287. https://doi.org/10.1182/blood-2014-01-545020CrossRefPubMed

225.

Wang, X., Chang, W. C., Wong, C. W., Colcher, D., Sherman, M., Ostberg, J. R., Forman, S. J., Riddell, S. R., & Jensen, M. C. (2011). A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood, 118(5), 1255–1263. https://doi.org/10.1182/blood-2011-02-337360CrossRefPubMedPubMedCentral

226.

Paszkiewicz, P. J., Fräßle, S. P., Srivastava, S., Sommermeyer, D., Hudecek, M., Drexler, I., Sadelain, M., Liu, L., Jensen, M. C., Riddell, S. R., & Busch, D. H. (2016). Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. The Journal of Clinical Investigation, 126(11), 4262–4272. https://doi.org/10.1172/jci84813CrossRefPubMedPubMedCentral

227.

Shabaneh, T. B., Moffett, H. F., Stull, S. M., Derezes, T., Tait, L. J., Park, S., Riddell, S. R., & Lajoie, M. J. (2022). Safety switch optimization enhances antibody-mediated elimination of CAR T cells [Original Research]. Frontiers in Molecular Medicine, 2. https://doi.org/10.3389/fmmed.2022.1026474

228.

Navarro, S. A., Carrillo, E., Griñán-Lisón, C., Martín, A., Perán, M., Marchal, J. A., & Boulaiz, H. (2016). Cancer suicide gene therapy: A patent review. Expert Opinion on Therapeutic Patents, 26(9), 1095–1104. https://doi.org/10.1080/13543776.2016.1211640CrossRefPubMed

229.

Zhou, X., & Brenner, M. K. (2016). Improving the safety of T-cell therapies using an inducible caspase-9 gene. Experimental Hematology, 44(11), 1013–1019. https://doi.org/10.1016/j.exphem.2016.07.011CrossRefPubMedPubMedCentral

230.

Stavrou, M., Philip, B., Traynor-White, C., Davis, C. G., Onuoha, S., Cordoba, S., Thomas, S., & Pule, M. (2018). A rapamycin-activated caspase 9-based suicide gene. Molecular Therapy, 26(5), 1266–1276. https://doi.org/10.1016/j.ymthe.2018.03.001CrossRefPubMedPubMedCentral

231.

Tey, S. K., Dotti, G., Rooney, C. M., Heslop, H. E., & Brenner, M. K. (2007). Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biology of Blood and Marrow Transplantation, 13(8), 913–924. https://doi.org/10.1016/j.bbmt.2007.04.005CrossRefPubMedPubMedCentral

232.

Di Stasi, A., Tey, S. K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., Liu, H., Cruz, C. R., Savoldo, B., Gee, A. P., Schindler, J., Krance, R. A., Heslop, H. E., Spencer, D. M., Rooney, C. M., & Brenner, M. K. (2011). Inducible apoptosis as a safety switch for adoptive cell therapy. New England Journal of Medicine, 365(18), 1673–1683. https://doi.org/10.1056/NEJMoa1106152CrossRefPubMed

233.

Zhou, X., Di Stasi, A., Tey, S. K., Krance, R. A., Martinez, C., Leung, K. S., Durett, A. G., Wu, M. F., Liu, H., Leen, A. M., Savoldo, B., Lin, Y. F., Grilley, B. J., Gee, A. P., Spencer, D. M., Rooney, C. M., Heslop, H. E., Brenner, M. K., & Dotti, G. (2014). Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene. Blood, 123(25), 3895–3905. https://doi.org/10.1182/blood-2014-01-551671CrossRefPubMedPubMedCentral

234.

Bouquet, L., Bôle-Richard, E., Warda, W., Neto Da Rocha, M., Trad, R., Nicod, C., Haderbache, R., Genin, D., Ferrand, C., & Deschamps, M. (2023). RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells. Gene Therapy, 30(9), 706–713. https://doi.org/10.1038/s41434-023-00404-2CrossRefPubMedPubMedCentral

235.

Thomis, D. C., Marktel, S., Bonini, C., Traversari, C., Gilman, M., Bordignon, C., & Clackson, T. (2001). A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood, 97(5), 1249–1257. https://doi.org/10.1182/blood.v97.5.1249CrossRefPubMed

236.

Richman, S. A., Wang, L. C., Moon, E. K., Khire, U. R., Albelda, S. M., & Milone, M. C. (2020). Ligand-induced degradation of a CAR permits reversible remote control of CAR T cell activity in vitro and in vivo. Molecular Therapy, 28(7), 1600–1613. https://doi.org/10.1016/j.ymthe.2020.06.004CrossRefPubMedPubMedCentral

237.

Rodgers, D. T., Mazagova, M., Hampton, E. N., Cao, Y., Ramadoss, N. S., Hardy, I. R., Schulman, A., Du, J., Wang, F., Singer, O., Ma, J., Nunez, V., Shen, J., Woods, A. K., Wright, T. M., Schultz, P. G., Kim, C. H., & Young, T. S. (2016). Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci U S A, 113(4), E459-468. https://doi.org/10.1073/pnas.1524155113CrossRefPubMedPubMedCentral

238.

Staedtke, V., Bai, R. Y., Kim, K., Darvas, M., Davila, M. L., Riggins, G. J., Rothman, P. B., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., & Zhou, S. (2018). Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome. Nature, 564(7735), 273–277. https://doi.org/10.1038/s41586-018-0774-yCrossRefPubMedPubMedCentral

239.

Leen, A. M., Sukumaran, S., Watanabe, N., Mohammed, S., Keirnan, J., Yanagisawa, R., Anurathapan, U., Rendon, D., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Vera, J. F. (2014). Reversal of tumor immune inhibition using a chimeric cytokine receptor. Molecular Therapy, 22(6), 1211–1220. https://doi.org/10.1038/mt.2014.47CrossRefPubMedPubMedCentral

240.

Juillerat, A., Marechal, A., Filhol, J. M., Valogne, Y., Valton, J., Duclert, A., Duchateau, P., & Poirot, L. (2017). An oxygen sensitive self-decision making engineered CAR T-cell. Science and Reports, 7, 39833. https://doi.org/10.1038/srep39833CrossRef

241.

Gazeau, N., Liang, E. C., Wu, Q. V., Voutsinas, J. M., Barba, P., Iacoboni, G., Kwon, M., Ortega, J. L. R., López-Corral, L., Hernani, R., Ortiz-Maldonado, V., Martínez-Cibrian, N., Martinez, A. P., Maziarz, R. T., Williamson, S., Nemecek, E. R., Shadman, M., Cowan, A. J., Green, D. J., . . . Gauthier, J. (2023). Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy. Transplantation and Cellular Therapy, 29(7), 430–437. https://doi.org/10.1016/j.jtct.2023.04.001

242.

Narkhede, M., Stasi, A. D., Bal, S., Shea, L. K., Goyal, G., Sledge, A., Hardwick, P., Giri, S., & Mehta, A. (2023). Interim analysis of investigator-initiated phase 2 trial of siltuximab in treatment of cytokine release syndrome and immune effector cell associated neurotoxicity related to CAR T-cell therapy. Transplantation and Cellular Therapy, Official Publication of the American Society for Transplantation and Cellular Therapy, 29(2), S133–S134. https://doi.org/10.1016/S2666-6367(23)00234-8CrossRef

243.

Nishimoto, N., Terao, K., Mima, T., Nakahara, H., Takagi, N., & Kakehi, T. (2008). Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood, 112(10), 3959–3964. https://doi.org/10.1182/blood-2008-05-155846CrossRefPubMed

244.

Rocco, J. M., Inglefield, J., Yates, B., Lichtenstein, D. A., Wang, Y., Goffin, L., Filipovic, D., Schiffrin, E. J., & Shah, N. N. (2023). Free interleukin-18 is elevated in CD22 CAR T-cell-associated hemophagocytic lymphohistiocytosis-like toxicities. Blood Advances, 7(20), 6134–6139. https://doi.org/10.1182/bloodadvances.2023010708CrossRefPubMedPubMedCentral

245.

Manni, S., Del Bufalo, F., Merli, P., Silvestris, D. A., Guercio, M., Caruso, S., Reddel, S., Iaffaldano, L., Pezzella, M., Di Cecca, S., Sinibaldi, M., Ottaviani, A., Quadraccia, M. C., Aurigemma, M., Sarcinelli, A., Ciccone, R., Abbaszadeh, Z., Ceccarelli, M., De Vito, R., . . . Quintarelli, C. (2023). Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. Nature Communications, 14(1), 3423. https://doi.org/10.1038/s41467-023-38723-y

246.

Bailey, S. R., Vatsa, S., Larson, R. C., Bouffard, A. A., Scarfò, I., Kann, M. C., Berger, T. R., Leick, M. B., Wehrli, M., Schmidts, A., Silva, H., Lindell, K. A., Demato, A., Gallagher, K. M. E., Frigault, M. J., & Maus, M. V. (2022). Blockade or deletion of IFNγ reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies. Blood Cancer Discov, 3(2), 136–153. https://doi.org/10.1158/2643-3230.Bcd-21-0181CrossRefPubMedPubMedCentral

247.

McNerney, K. O., DiNofia, A. M., Teachey, D. T., Grupp, S. A., & Maude, S. L. (2022). Potential role of IFNγ inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy. Blood Cancer Discovery, 3(2), 90–94. https://doi.org/10.1158/2643-3230.Bcd-21-0203CrossRefPubMedPubMedCentral

248.

Sterner, R. M., Cox, M. J., Sakemura, R., & Kenderian, S. S. (2019). Using CRISPR/Cas9 to knock out GM-CSF in CAR-T cells. Journal of Visualized Experiments (149). https://doi.org/10.3791/59629

249.

Sachdeva, M., Duchateau, P., Depil, S., Poirot, L., & Valton, J. (2019). Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. Journal of Biological Chemistry, 294(14), 5430–5437. https://doi.org/10.1074/jbc.AC119.007558CrossRefPubMedPubMedCentral

250.

Mestermann, K., Giavridis, T., Weber, J., Rydzek, J., Frenz, S., Nerreter, T., Mades, A., Sadelain, M., Einsele, H., & Hudecek, M. (2019). The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells. Science Translational Medicine, 11(499). https://doi.org/10.1126/scitranslmed.aau5907

251.

Weber, E. W., Lynn, R. C., Sotillo, E., Lattin, J., Xu, P., & Mackall, C. L. (2019). Pharmacologic control of CAR-T cell function using dasatinib. Blood Advances, 3(5), 711–717. https://doi.org/10.1182/bloodadvances.2018028720CrossRefPubMedPubMedCentral

252.

Baur, K., Heim, D., Beerlage, A., Poerings, A. S., Kopp, B., Medinger, M., Dirks, J. C., Passweg, J. R., & Holbro, A. (2022). Dasatinib for treatment of CAR T-cell therapy-related complications. Journal for immunotherapy of cancer, 10(12). https://doi.org/10.1136/jitc-2022-005956

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Evolving strategies for addressing CAR T-cell toxicities

Abstract

Other articles of this Issue 1/2025

Homologous recombination deficiency (HRD) diagnostics: underlying mechanisms and new perspectives

Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities

Neuropeptide Y in cancer—biological functions and potential clinical implications

Recapitulating the potential contribution of protein S-palmitoylation in cancer

CAR T-cell therapy to treat multiple myeloma: current state and future directions

Small cell lung cancer with liver metastases: from underlying mechanisms to treatment strategies

ASH 2024 Annual Meeting Coverage

inMIND supports tafasitamab addition in follicular lymphoma

Transplantation can be omitted for certain MCL patients

Add-on blinatumomab improves DFS in children with ALL

Promising response to loncastuximab tesirine in lymphoma

» View more highlights on the ASH 2024 hub page

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Keynote webinar | Spotlight on adolescent vaping

Springer Medicine

Abstract

Please log in to get access to this content

ASH 2024 Annual Meeting Coverage